response_type,drug,Primary Tumor type,association,genes,mutation,mutation
missense,Imatinib,lung adenocarcinoma,sensitive,ABL1,R332W,ABL1 R332W
missense,DASATINIB,lung adenocarcinoma,sensitive,ABL1,R332W,ABL1 R332W
missense,DASATINIB,lung adenocarcinoma,sensitive,ABL1,G321L,ABL1 G321L
missense,Imatinib,lung adenocarcinoma,sensitive,ABL1,G321L,ABL1 G321L
missense,Capivasertib,Her2-receptor negative breast cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,UPROSERTIB,melanoma (disease),sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,endometrial cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,IPATASERTIB,Her2-receptor negative breast cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,lung adenocarcinoma,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,cervical cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,estrogen-receptor positive breast cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,triple-negative breast carcinoma,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,meningothelial meningioma,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,breast cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,breast cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,parotid gland cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,leiomyosarcoma of the corpus uteri,sensitive,AKT1,E17K,AKT1 E17K
missense,UPROSERTIB,cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,endometrium adenocarcinoma,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,granulosa cell tumor,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,ovarian endometrial cancer,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,breast papillary carcinoma,sensitive,AKT1,E17K,AKT1 E17K
missense,Capivasertib,ovarian cancer,sensitive,AKT1,Q79K,AKT1 Q79K
missense,CERITINIB,ganglioneuroblastoma (disease),sensitive,ALK,I1171T,ALK I1171T
missense,BRIGATINIB,cancer,sensitive,ALK,G1128A,ALK G1128A
missense,BRIGATINIB,cancer,sensitive,ALK,F1174L,ALK F1174L
missense,CRIZOTINIB,neuroblastoma,resistant,ALK,F1174L,ALK F1174L
missense,LORLATINIB,cancer,sensitive,ALK,F1174L,ALK F1174L
missense,BRIGATINIB,cancer,sensitive,ALK,I1171N,ALK I1171N
missense,CRIZOTINIB,neuroblastoma,sensitive,ALK,R1275Q,ALK R1275Q
missense,Cyclophosphamide,neuroblastoma,sensitive,ALK,R1275Q,ALK R1275Q
missense,Topotecan,neuroblastoma,sensitive,ALK,R1275Q,ALK R1275Q
missense,BRIGATINIB,cancer,sensitive,ALK,R1275Q,ALK R1275Q
missense,LORLATINIB,neuroblastoma,sensitive,ALK,R1275Q,ALK R1275Q
missense,CERITINIB,neuroblastoma,sensitive,ALK,R1275Q,ALK R1275Q
missense,LORLATINIB,cancer,sensitive,ALK,R1275Q,ALK R1275Q
missense,ALECTINIB,cancer,sensitive,ALK,C1156Y,ALK C1156Y
missense,CRIZOTINIB,neuroblastoma,resistant,ALK,F1245C,ALK F1245C
missense,BRIGATINIB,cancer,sensitive,ALK,F1245C,ALK F1245C
missense,LORLATINIB,neuroblastoma,sensitive,ALK,F1245C,ALK F1245C
missense,LORLATINIB,cancer,sensitive,ALK,F1245C,ALK F1245C
missense,BRIGATINIB,cancer,sensitive,ALK,Y1278S,ALK Y1278S
missense,ALECTINIB,neuroblastoma,sensitive,ALK,D1091N,ALK D1091N
missense,ALECTINIB,neuroblastoma,sensitive,ALK,D1091N,ALK D1091N
missense,Doxorubicin,neuroblastoma,sensitive,ALK,D1091N,ALK D1091N
missense,Doxorubicin,neuroblastoma,sensitive,ALK,D1091N,ALK D1091N
missense,ENTRECTINIB,neuroblastoma,sensitive,ALK,F1245V,ALK F1245V
missense,BRIGATINIB,neuroblastoma,sensitive,ALK,F1174V,ALK F1174V
missense,BRIGATINIB,cancer,sensitive,ALK,G1269A,ALK G1269A
missense,BRIGATINIB,cancer,sensitive,ALK,R1192P,ALK R1192P
missense,OLAPARIB,colorectal cancer,sensitive,ARID1A,Q456*,ARID1A Q456*
missense,RUCAPARIB,colorectal cancer,sensitive,ARID1A,Q456*,ARID1A Q456*
missense,DASATINIB,colorectal cancer,sensitive,ARID1A,Q456*,ARID1A Q456*
missense,BERZOSERTIB,colorectal cancer,sensitive,ARID1A,Q456*,ARID1A Q456*
missense,VEMURAFENIB,cancer,resistant,BRAF,G464E,BRAF G464E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600R,BRAF V600R
missense,malathion,melanoma (disease),sensitive,BRAF,V600R,BRAF V600R
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600R,BRAF V600R
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600R,BRAF V600R
missense,VEMURAFENIB,cancer,resistant,BRAF,K601T,BRAF K601T
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,G596R,BRAF G596R
missense,TRAMETINIB,colorectal cancer,sensitive,BRAF,G596R,BRAF G596R
missense,TRAMETINIB,colorectal cancer,sensitive,BRAF,G596R,BRAF G596R
missense,VEMURAFENIB,colorectal cancer,resistant,BRAF,G596R,BRAF G596R
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600D,BRAF V600D
missense,malathion,melanoma (disease),sensitive,BRAF,V600D,BRAF V600D
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600D,BRAF V600D
missense,DABRAFENIB,pilocytic astrocytoma,sensitive,BRAF,V600D,BRAF V600D
missense,TRAMETINIB,pilocytic astrocytoma,sensitive,BRAF,V600D,BRAF V600D
missense,VEMURAFENIB,cancer,resistant,BRAF,K601N,BRAF K601N
missense,VEMURAFENIB,cancer,resistant,BRAF,G464R,BRAF G464R
missense,Sorafenib,non-small cell lung carcinoma (disease),sensitive,BRAF,G469V,BRAF G469V
missense,VEMURAFENIB,cancer,resistant,BRAF,G469V,BRAF G469V
missense,ENCORAFENIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,COBIMETINIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,BINIMETINIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,ENCORAFENIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,malathion,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,TRAMETINIB,cancer,sensitive,BRAF,L597S,BRAF L597S
missense,BINIMETINIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,ENCORAFENIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,VEMURAFENIB,cancer,sensitive,BRAF,L597S,BRAF L597S
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,L597S,BRAF L597S
missense,REFAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PLX-4720,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,BINIMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,ENCORAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,CEDIRANIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,SELUMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Irinotecan,rectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,rectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Sorbinil,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,GSK2126458,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PIMASERTIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Sorafenib,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,neuroendocrine neoplasm,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,neuroendocrine neoplasm,sensitive,BRAF,V600E,BRAF V600E
missense,Sorafenib,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DASATINIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,REFAMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,malignant glioma,sensitive,BRAF,V600E,BRAF V600E
missense,ENCORAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,neuroendocrine neoplasm,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,neuroendocrine neoplasm,sensitive,BRAF,V600E,BRAF V600E
missense,DASATINIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Lapatinib,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,PANOBINOSTAT,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Irinotecan,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,Ulixertinib,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,CI-1040,cancer,sensitive,BRAF,V600E,BRAF V600E
missense,PLX-4720,glioma susceptibility 1,resistant,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PLX8394,cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,SELUMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,RO-5126766 free base,thyroid gland papillary carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,malathion,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PALBOCICLIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Irinotecan,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,BI 2536,glioma susceptibility 1,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,CI-1040,ovarian cancer,sensitive,BRAF,V600E,BRAF V600E
missense,RO-5126766 free base,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Sorbinil,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VORINOSTAT,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Lifirafenib,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Lifirafenib,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,malathion,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Agerafenib,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,hairy cell leukemia,sensitive,BRAF,V600E,BRAF V600E
missense,ALPELISIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DASATINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,melanoma (disease),resistant,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),resistant,BRAF,V600E,BRAF V600E
missense,Imatinib,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PIMASERTIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,COBIMETINIB,lymphatic system cancer,sensitive,BRAF,V600E,BRAF V600E
missense,PIMASERTIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colon neuroendocrine neoplasm,sensitive,BRAF,V600E,BRAF V600E
missense,AFATINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PD-0325901,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,GEDATOLISIB,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Erlotinib,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,COBIMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,larynx cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Ulixertinib,glioma susceptibility 1,sensitive,BRAF,V600E,BRAF V600E
missense,Lapatinib,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,ENCORAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,GEFITINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PLX-4720,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,pleomorphic xanthoastrocytoma,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,pleomorphic xanthoastrocytoma,sensitive,BRAF,V600E,BRAF V600E
missense,RAF-265,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PLX-4720,cancer,sensitive,BRAF,V600E,BRAF V600E
missense,GEFITINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,COBIMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,PLX-4720,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,malathion,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Erlotinib,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Lifirafenib,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Lifirafenib,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PD-0325901,glioma susceptibility 1,resistant,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,SELUMETINIB,malignant glioma,sensitive,BRAF,V600E,BRAF V600E
missense,Sorafenib,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,Irinotecan,rectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,rectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Ulixertinib,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,BI 2536,glioma susceptibility 1,sensitive,BRAF,V600E,BRAF V600E
missense,PLX-4720,glioma susceptibility 1,sensitive,BRAF,V600E,BRAF V600E
missense,Ulixertinib,lung cancer,sensitive,BRAF,V600E,BRAF V600E
missense,SELUMETINIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,4-DEOXYLACTOSE,colorectal adenocarcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,ENCORAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Ribociclib,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,ENCORAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,SELUMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Sorbinil,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Doxorubicin,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,GANETESPIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,renal cell adenocarcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,FLUOROURACIL,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,SARACATINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,SELUMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,4-DEOXYLACTOSE,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DASATINIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,SELUMETINIB,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,SELUMETINIB,malignant glioma,sensitive,BRAF,V600E,BRAF V600E
missense,SELUMETINIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,GANETESPIB,cutaneous melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,PIMASERTIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,REGORAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,pleomorphic xanthoastrocytoma,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,pilocytic astrocytoma,sensitive,BRAF,V600E,BRAF V600E
missense,RAF-265,cancer,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,colon carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,DASATINIB,lung carcinoma,resistant,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,ovarian cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,glioma susceptibility 1,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,glioma susceptibility 1,sensitive,BRAF,V600E,BRAF V600E
missense,PD-0325901,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,COBIMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,ALPELISIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,ENCORAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,ganglioglioma,sensitive,BRAF,V600E,BRAF V600E
missense,DABRAFENIB,salivary gland carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,salivary gland carcinoma,sensitive,BRAF,V600E,BRAF V600E
missense,TIVOZANIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,REGORAFENIB,colorectal cancer,sensitive,BRAF,V600E,BRAF V600E
missense,CEDIRANIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,Agerafenib,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,malathion,thyroid cancer,sensitive,BRAF,V600E,BRAF V600E
missense,VEMURAFENIB,cancer,sensitive,BRAF,V600E,BRAF V600E
missense,Lifirafenib,cancer,sensitive,BRAF,V600E,BRAF V600E
missense,BINIMETINIB,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,RO4987655,melanoma (disease),sensitive,BRAF,V600E,BRAF V600E
missense,TRAMETINIB,cancer,sensitive,BRAF,F247L,BRAF F247L
missense,DABRAFENIB,cancer,sensitive,BRAF,F247L,BRAF F247L
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,K601E,BRAF K601E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,K601E,BRAF K601E
missense,TRAMETINIB,cancer,sensitive,BRAF,K601E,BRAF K601E
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,GSK2126458,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,COBIMETINIB,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600K,BRAF V600K
missense,COBIMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,COBIMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,Navtemadlin,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,SELUMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,cholangiocarcinoma,sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,colorectal cancer,sensitive,BRAF,V600X,BRAF V600X
missense,COBIMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,Irinotecan,colorectal cancer,sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,colorectal cancer,sensitive,BRAF,V600X,BRAF V600X
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,BUPARLISIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,BINIMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,BUPARLISIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,SELUMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,DABRAFENIB,colorectal cancer,sensitive,BRAF,V600X,BRAF V600X
missense,TRAMETINIB,colorectal cancer,sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,thyroid cancer,sensitive,BRAF,V600X,BRAF V600X
missense,BUPARLISIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600X,BRAF V600X
missense,VEMURAFENIB,melanoma (disease),resistant,BRAF,L505H,BRAF L505H
missense,VEMURAFENIB,cancer,resistant,BRAF,G464V,BRAF G464V
missense,VEMURAFENIB,cancer,resistant,BRAF,G464V,BRAF G464V
missense,Irinotecan,colorectal cancer,sensitive,BRAF,G466V,BRAF G466V
missense,TRAMETINIB,colorectal cancer,sensitive,BRAF,G466V,BRAF G466V
missense,malathion,non-small cell lung carcinoma (disease),sensitive,BRAF,G466V,BRAF G466V
missense,DASATINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G466V,BRAF G466V
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G466V,BRAF G466V
missense,PLX8394,lung adenocarcinoma,sensitive,BRAF,G466V,BRAF G466V
missense,DABRAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G466V,BRAF G466V
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G466V,BRAF G466V
missense,VEMURAFENIB,non-small cell lung carcinoma (disease),resistant,BRAF,G466V,BRAF G466V
missense,VEMURAFENIB,cancer,resistant,BRAF,L597Q,BRAF L597Q
missense,VEMURAFENIB,cancer,resistant,BRAF,L597Q,BRAF L597Q
missense,Ulixertinib,lung cancer,sensitive,BRAF,L597Q,BRAF L597Q
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,D594G,BRAF D594G
missense,VEMURAFENIB,cancer,sensitive,BRAF,L597R,BRAF L597R
missense,TRAMETINIB,cancer,sensitive,BRAF,L597R,BRAF L597R
missense,VEMURAFENIB,cancer,resistant,BRAF,F595L,BRAF F595L
missense,DABRAFENIB,breast cancer,resistant,BRAF,L514V,BRAF L514V
missense,Ulixertinib,gallbladder cancer,sensitive,BRAF,L485W,BRAF L485W
missense,malathion,melanoma (disease),sensitive,BRAF,G466E,BRAF G466E
missense,DABRAFENIB,melanoma (disease),resistant,BRAF,G466E,BRAF G466E
missense,VEMURAFENIB,melanoma (disease),resistant,BRAF,G466E,BRAF G466E
missense,COBIMETINIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,DABRAFENIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,BINIMETINIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,ENCORAFENIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,BINIMETINIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,ENCORAFENIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,BINIMETINIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,ENCORAFENIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,VEMURAFENIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,TRAMETINIB,melanoma (disease),sensitive,BRAF,V600E/K,BRAF V600E/K
missense,VEMURAFENIB,cancer,resistant,BRAF,D594N,BRAF D594N
missense,VEMURAFENIB,cancer,resistant,BRAF,L597V,BRAF L597V
missense,DASATINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,Y472C,BRAF Y472C
missense,VEMURAFENIB,non-small cell lung carcinoma (disease),resistant,BRAF,G469A,BRAF G469A
missense,ENCORAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G469A,BRAF G469A
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G469A,BRAF G469A
missense,PLX8394,lung adenocarcinoma,sensitive,BRAF,G469A,BRAF G469A
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G469A,BRAF G469A
missense,Ulixertinib,head and neck cancer,sensitive,BRAF,G469A,BRAF G469A
missense,VEMURAFENIB,cancer,resistant,BRAF,G469A,BRAF G469A
missense,VEMURAFENIB,cancer,resistant,BRAF,G469A,BRAF G469A
missense,Ulixertinib,small intestine carcinoma,sensitive,BRAF,G469A,BRAF G469A
missense,DABRAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G469A,BRAF G469A
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G469A,BRAF G469A
missense,DABRAFENIB,non-small cell lung carcinoma (disease),sensitive,BRAF,G469A,BRAF G469A
missense,DINACICLIB,triple-negative breast carcinoma,sensitive,BRCA1,R1443*,BRCA1 R1443*
missense,VELIPARIB,triple-negative breast carcinoma,sensitive,BRCA1,R1443*,BRCA1 R1443*
missense,RUCAPARIB,ovarian carcinoma,sensitive,BRCA1,N682*,BRCA1 N682*
missense,RUCAPARIB,ovarian carcinoma,sensitive,BRCA1,W1782*,BRCA1 W1782*
missense,DINACICLIB,triple-negative breast carcinoma,sensitive,BRCA2,S1970*,BRCA2 S1970*
missense,VELIPARIB,triple-negative breast carcinoma,sensitive,BRCA2,S1970*,BRCA2 S1970*
missense,PALBOCICLIB,gastric carcinoma,sensitive,CDKN2A,R80*,CDKN2A R80*
missense,Imatinib,myeloid leukemia,sensitive,CSF1R,Y571D,CSF1R Y571D
missense,RUXOLITINIB,cancer,sensitive,CSF3R,N610S,CSF3R N610S
missense,TRAMETINIB,cancer,sensitive,CSF3R,N610S,CSF3R N610S
missense,IBRUTINIB,cancer,sensitive,CSF3R,Q741*,CSF3R Q741*
missense,RUXOLITINIB,cancer,sensitive,CSF3R,Q741*,CSF3R Q741*
missense,RUXOLITINIB,cancer,sensitive,CSF3R,Q741*,CSF3R Q741*
missense,IBRUTINIB,cancer,sensitive,CSF3R,Q741*,CSF3R Q741*
missense,RUXOLITINIB,cancer,sensitive,CSF3R,N610H,CSF3R N610H
missense,TRAMETINIB,cancer,sensitive,CSF3R,N610H,CSF3R N610H
missense,IBRUTINIB,cancer,sensitive,CSF3R,T618I,CSF3R T618I
missense,IBRUTINIB,cancer,sensitive,CSF3R,T618I,CSF3R T618I
missense,RUXOLITINIB,cancer,sensitive,CSF3R,T618I,CSF3R T618I
missense,RUXOLITINIB,cancer,sensitive,CSF3R,T618I,CSF3R T618I
missense,RUXOLITINIB,cancer,sensitive,CSF3R,T640N,CSF3R T640N
missense,Imatinib,desmoid tumor,sensitive,CTNNB1,T41A,CTNNB1 T41A
missense,Imatinib,desmoid tumor,sensitive,CTNNB1,S45F,CTNNB1 S45F
missense,Lapatinib,breast cancer,resistant,ERBB2,L726F,ERBB2 L726F
missense,Lapatinib,cancer,resistant,ERBB2,L726F,ERBB2 L726F
missense,AFATINIB,lung adenocarcinoma,sensitive,ERBB2,N813D,ERBB2 N813D
missense,Lapatinib,cancer,sensitive,ERBB2,H878Y,ERBB2 H878Y
missense,AEE-788,cancer,sensitive,ERBB2,H878Y,ERBB2 H878Y
missense,NERATINIB,urinary bladder cancer,resistant,ERBB2,D769Y,ERBB2 D769Y
missense,NERATINIB,breast cancer,sensitive,ERBB2,D769Y,ERBB2 D769Y
missense,Lapatinib,breast cancer,sensitive,ERBB2,D769Y,ERBB2 D769Y
missense,NERATINIB,gastroesophageal junction adenocarcinoma,resistant,ERBB2,D769Y,ERBB2 D769Y
missense,Lapatinib,cancer,resistant,ERBB2,T733I,ERBB2 T733I
missense,Lapatinib,breast cancer,sensitive,ERBB2,T798M,ERBB2 T798M
missense,Lapatinib,breast cancer,sensitive,ERBB2,T798M,ERBB2 T798M
missense,Lapatinib,Her2-receptor positive breast cancer,resistant,ERBB2,T798M,ERBB2 T798M
missense,Lapatinib,cancer,resistant,ERBB2,T798M,ERBB2 T798M
missense,AEE-788,cancer,resistant,ERBB2,T798M,ERBB2 T798M
missense,CI-1040,breast cancer,resistant,ERBB2,T798M,ERBB2 T798M
missense,BUPARLISIB,breast cancer,sensitive,ERBB2,T798M,ERBB2 T798M
missense,AFATINIB,breast cancer,sensitive,ERBB2,T798M,ERBB2 T798M
missense,Pilaralisib,breast cancer,sensitive,ERBB2,T798M,ERBB2 T798M
missense,Lapatinib,cancer,sensitive,ERBB2,G660R,ERBB2 G660R
missense,NERATINIB,cancer,sensitive,ERBB2,G660R,ERBB2 G660R
missense,AFATINIB,cancer,sensitive,ERBB2,G660R,ERBB2 G660R
missense,NERATINIB,breast cancer,sensitive,ERBB2,V773L,ERBB2 V773L
missense,Lapatinib,breast cancer,sensitive,ERBB2,V773L,ERBB2 V773L
missense,NERATINIB,colorectal cancer,resistant,ERBB2,G778A,ERBB2 G778A
missense,NERATINIB,cervical cancer,resistant,ERBB2,S310Y,ERBB2 S310Y
missense,NERATINIB,colorectal cancer,sensitive,ERBB2,S310Y,ERBB2 S310Y
missense,AFATINIB,squamous cell lung carcinoma,sensitive,ERBB2,S310Y,ERBB2 S310Y
missense,NERATINIB,gastroesophageal junction adenocarcinoma,resistant,ERBB2,S310Y,ERBB2 S310Y
missense,NERATINIB,colorectal cancer,sensitive,ERBB2,S310Y,ERBB2 S310Y
missense,Lapatinib,colorectal cancer,sensitive,ERBB2,S310Y,ERBB2 S310Y
missense,Lapatinib,colorectal cancer,sensitive,ERBB2,S310Y,ERBB2 S310Y
missense,Mobocertinib,cancer,sensitive,ERBB2,G776V,ERBB2 G776V
missense,Lapatinib,cancer,resistant,ERBB2,S783P,ERBB2 S783P
missense,Lapatinib,cancer,resistant,ERBB2,V773A,ERBB2 V773A
missense,AEE-788,cancer,sensitive,ERBB2,V773A,ERBB2 V773A
missense,AEE-788,cancer,resistant,ERBB2,L755S,ERBB2 L755S
missense,Lapatinib,Her2-receptor positive breast cancer,resistant,ERBB2,L755S,ERBB2 L755S
missense,Lapatinib,cancer,resistant,ERBB2,L755S,ERBB2 L755S
missense,NERATINIB,breast cancer,sensitive,ERBB2,L755S,ERBB2 L755S
missense,NERATINIB,colorectal cancer,sensitive,ERBB2,L755S,ERBB2 L755S
missense,NERATINIB,colon carcinoma,sensitive,ERBB2,L755S,ERBB2 L755S
missense,NERATINIB,colon carcinoma,sensitive,ERBB2,L755S,ERBB2 L755S
missense,NERATINIB,Her2-receptor negative breast cancer,sensitive,ERBB2,L755S,ERBB2 L755S
missense,AFATINIB,colorectal cancer,sensitive,ERBB2,L755S,ERBB2 L755S
missense,NERATINIB,non-small cell lung carcinoma (disease),sensitive,ERBB2,L755S,ERBB2 L755S
missense,NERATINIB,breast cancer,sensitive,ERBB2,R678Q,ERBB2 R678Q
missense,NERATINIB,cancer,sensitive,ERBB2,R678Q,ERBB2 R678Q
missense,Lapatinib,breast cancer,sensitive,ERBB2,R678Q,ERBB2 R678Q
missense,Lapatinib,cancer,sensitive,ERBB2,R678Q,ERBB2 R678Q
missense,NERATINIB,gastroesophageal junction adenocarcinoma,resistant,ERBB2,R678Q,ERBB2 R678Q
missense,AFATINIB,cancer,sensitive,ERBB2,R678Q,ERBB2 R678Q
missense,NERATINIB,colorectal cancer,resistant,ERBB2,R678Q,ERBB2 R678Q
missense,Lapatinib,cancer,resistant,ERBB2,L785F,ERBB2 L785F
missense,Lapatinib,cancer,resistant,ERBB2,Y803N,ERBB2 Y803N
missense,Lapatinib,cancer,resistant,ERBB2,T798I,ERBB2 T798I
missense,Lapatinib,lung cancer,resistant,ERBB2,T798I,ERBB2 T798I
missense,AEE-788,cancer,resistant,ERBB2,L755P,ERBB2 L755P
missense,Lapatinib,cancer,resistant,ERBB2,L755P,ERBB2 L755P
missense,Lapatinib,breast cancer,sensitive,ERBB2,G309A,ERBB2 G309A
missense,NERATINIB,breast cancer,sensitive,ERBB2,G309A,ERBB2 G309A
missense,NERATINIB,colon carcinoma,sensitive,ERBB2,V777L,ERBB2 V777L
missense,Lapatinib,breast cancer,sensitive,ERBB2,V777L,ERBB2 V777L
missense,AFATINIB,colorectal cancer,sensitive,ERBB2,V777L,ERBB2 V777L
missense,NERATINIB,Her2-receptor negative breast cancer,sensitive,ERBB2,V777L,ERBB2 V777L
missense,AEE-788,cancer,sensitive,ERBB2,V777L,ERBB2 V777L
missense,NERATINIB,gastroesophageal junction adenocarcinoma,resistant,ERBB2,V777L,ERBB2 V777L
missense,NERATINIB,colorectal cancer,sensitive,ERBB2,V777L,ERBB2 V777L
missense,Lapatinib,cancer,sensitive,ERBB2,V777L,ERBB2 V777L
missense,NERATINIB,breast cancer,sensitive,ERBB2,V777L,ERBB2 V777L
missense,NERATINIB,triple-negative breast carcinoma,sensitive,ERBB2,V697L,ERBB2 V697L
missense,NERATINIB,endometrial cancer,resistant,ERBB2,V697L,ERBB2 V697L
missense,NERATINIB,cancer,sensitive,ERBB2,V697L,ERBB2 V697L
missense,NERATINIB,urinary bladder cancer,resistant,ERBB2,G292R,ERBB2 G292R
missense,NERATINIB,colorectal cancer,resistant,ERBB2,L841V,ERBB2 L841V
missense,AFATINIB,cancer,sensitive,ERBB2,G660D,ERBB2 G660D
missense,AFATINIB,lung cancer,sensitive,ERBB2,G660D,ERBB2 G660D
missense,AFATINIB,lung cancer,sensitive,ERBB2,G660D,ERBB2 G660D
missense,AFATINIB,lung cancer,sensitive,ERBB2,G660D,ERBB2 G660D
missense,NERATINIB,cancer,sensitive,ERBB2,G660D,ERBB2 G660D
missense,Lapatinib,cancer,sensitive,ERBB2,G660D,ERBB2 G660D
missense,Lapatinib,cancer,resistant,ERBB2,E719G,ERBB2 E719G
missense,Lapatinib,breast cancer,sensitive,ERBB2,L768S,ERBB2 L768S
missense,NERATINIB,breast cancer,sensitive,ERBB2,L768S,ERBB2 L768S
missense,NERATINIB,breast cancer,sensitive,ERBB2,K753E,ERBB2 K753E
missense,Lapatinib,breast cancer,resistant,ERBB2,K753E,ERBB2 K753E
missense,AFATINIB,colorectal cancer,sensitive,ERBB2,L866M,ERBB2 L866M
missense,NERATINIB,colorectal cancer,sensitive,ERBB2,L866M,ERBB2 L866M
missense,NERATINIB,colon carcinoma,sensitive,ERBB2,L866M,ERBB2 L866M
missense,AEE-788,cancer,sensitive,ERBB2,T862A,ERBB2 T862A
missense,Lapatinib,cancer,resistant,ERBB2,T862A,ERBB2 T862A
missense,Poziotinib,lung adenocarcinoma,sensitive,ERBB2,E812K,ERBB2 E812K
missense,Lapatinib,cancer,resistant,ERBB2,E812K,ERBB2 E812K
missense,AEE-788,cancer,sensitive,ERBB2,N857S,ERBB2 N857S
missense,Lapatinib,cancer,resistant,ERBB2,N857S,ERBB2 N857S
missense,Lapatinib,urinary bladder cancer,sensitive,ERBB2,S310F,ERBB2 S310F
missense,SELUMETINIB,urinary bladder cancer,resistant,ERBB2,S310F,ERBB2 S310F
missense,NERATINIB,Her2-receptor negative breast cancer,sensitive,ERBB2,S310F,ERBB2 S310F
missense,Lapatinib,cancer,sensitive,ERBB2,S310F,ERBB2 S310F
missense,AFATINIB,colorectal cancer,sensitive,ERBB2,S310F,ERBB2 S310F
missense,NERATINIB,cervical cancer,sensitive,ERBB2,S310F,ERBB2 S310F
missense,NERATINIB,non-small cell lung carcinoma (disease),resistant,ERBB2,S310F,ERBB2 S310F
missense,NERATINIB,colon carcinoma,sensitive,ERBB2,S310F,ERBB2 S310F
missense,AFATINIB,urinary bladder cancer,sensitive,ERBB2,S310F,ERBB2 S310F
missense,NERATINIB,cancer,sensitive,ERBB2,S310F,ERBB2 S310F
missense,NERATINIB,colorectal cancer,resistant,ERBB2,K831N,ERBB2 K831N
missense,NERATINIB,cancer,sensitive,ERBB2,V659E,ERBB2 V659E
missense,AFATINIB,lung cancer,sensitive,ERBB2,V659E,ERBB2 V659E
missense,TIVOZANIB,breast cancer,sensitive,ERBB2,V659E,ERBB2 V659E
missense,GEFITINIB,cancer,resistant,ERBB2,V659E,ERBB2 V659E
missense,Adenosine,lung adenocarcinoma,sensitive,ERBB2,V659E,ERBB2 V659E
missense,AFATINIB,cancer,sensitive,ERBB2,V659E,ERBB2 V659E
missense,Lapatinib,cancer,sensitive,ERBB2,V659E,ERBB2 V659E
missense,Lapatinib,breast cancer,sensitive,ERBB2,D769H,ERBB2 D769H
missense,NERATINIB,colorectal cancer,resistant,ERBB2,D769H,ERBB2 D769H
missense,NERATINIB,breast cancer,sensitive,ERBB2,D769H,ERBB2 D769H
missense,SELUMETINIB,urinary bladder cancer,resistant,ERBB2,S653C,ERBB2 S653C
missense,AFATINIB,urinary bladder cancer,sensitive,ERBB2,S653C,ERBB2 S653C
missense,Lapatinib,urinary bladder cancer,sensitive,ERBB2,S653C,ERBB2 S653C
missense,NERATINIB,cancer,sensitive,ERBB2,L663P,ERBB2 L663P
missense,Lapatinib,cancer,sensitive,ERBB2,L663P,ERBB2 L663P
missense,AFATINIB,cancer,sensitive,ERBB2,L663P,ERBB2 L663P
missense,NERATINIB,breast cancer,sensitive,ERBB2,V842I,ERBB2 V842I
missense,AFATINIB,colorectal cancer,sensitive,ERBB2,V842I,ERBB2 V842I
missense,NERATINIB,colon carcinoma,sensitive,ERBB2,V842I,ERBB2 V842I
missense,NERATINIB,endometrial cancer,resistant,ERBB2,V842I,ERBB2 V842I
missense,Lapatinib,breast cancer,sensitive,ERBB2,V842I,ERBB2 V842I
missense,NERATINIB,Her2-receptor negative breast cancer,sensitive,ERBB2,L869R,ERBB2 L869R
missense,Lapatinib,lung adenocarcinoma,resistant,ERBB2,L869R,ERBB2 L869R
missense,AFATINIB,breast cancer,sensitive,ERBB2,L869R,ERBB2 L869R
missense,NERATINIB,breast cancer,sensitive,ERBB2,L869R,ERBB2 L869R
missense,NERATINIB,breast cancer,sensitive,ERBB2,L869R,ERBB2 L869R
missense,Lapatinib,breast cancer,resistant,ERBB2,L869R,ERBB2 L869R
missense,Lapatinib,cancer,resistant,ERBB2,P780L,ERBB2 P780L
missense,Lapatinib,cancer,resistant,ERBB2,E717K,ERBB2 E717K
missense,NERATINIB,breast cancer,sensitive,ERBB2,R896C,ERBB2 R896C
missense,Lapatinib,breast cancer,sensitive,ERBB2,R896C,ERBB2 R896C
missense,AFATINIB,cancer,sensitive,ERBB2,Q709L,ERBB2 Q709L
missense,Lapatinib,cancer,sensitive,ERBB2,Q709L,ERBB2 Q709L
missense,GEFITINIB,breast cancer,resistant,ERBB2,L726I,ERBB2 L726I
missense,Lapatinib,melanoma (disease),sensitive,ERBB4,R393W,ERBB4 R393W
missense,AFATINIB,head and neck squamous cell carcinoma,sensitive,ERBB4,G1109C,ERBB4 G1109C
missense,Lapatinib,melanoma (disease),sensitive,ERBB4,E317K,ERBB4 E317K
missense,Lapatinib,melanoma (disease),sensitive,ERBB4,E452K,ERBB4 E452K
missense,Lapatinib,melanoma (disease),sensitive,ERBB4,R544W,ERBB4 R544W
missense,Lapatinib,melanoma (disease),sensitive,ERBB4,E563K,ERBB4 E563K
missense,Tazemetostat,non-Hodgkin lymphoma,sensitive,EZH2,Y646H,EZH2 Y646H
missense,Tazemetostat,cancer,resistant,EZH2,Y111D,EZH2 Y111D
missense,RICOLINOSTAT,diffuse large B-cell lymphoma,sensitive,EZH2,Y641S,EZH2 Y641S
missense,RICOLINOSTAT,diffuse large B-cell lymphoma,sensitive,EZH2,Y641S,EZH2 Y641S
missense,VORINOSTAT,diffuse large B-cell lymphoma,sensitive,EZH2,Y641S,EZH2 Y641S
missense,RICOLINOSTAT,diffuse large B-cell lymphoma,sensitive,EZH2,Y641S,EZH2 Y641S
missense,Tazemetostat,lymphoma,sensitive,EZH2,Y646F,EZH2 Y646F
missense,VORINOSTAT,diffuse large B-cell lymphoma,sensitive,EZH2,Y641N,EZH2 Y641N
missense,RICOLINOSTAT,diffuse large B-cell lymphoma,sensitive,EZH2,Y641N,EZH2 Y641N
missense,Doxorubicin,diffuse large B-cell lymphoma,sensitive,EZH2,Y641N,EZH2 Y641N
missense,RICOLINOSTAT,diffuse large B-cell lymphoma,sensitive,EZH2,Y641N,EZH2 Y641N
missense,RICOLINOSTAT,diffuse large B-cell lymphoma,sensitive,EZH2,Y641N,EZH2 Y641N
missense,RICOLINOSTAT,diffuse large B-cell lymphoma,sensitive,EZH2,Y641N,EZH2 Y641N
missense,REGORAFENIB,colorectal cancer,resistant,FBXW7,R505C,FBXW7 R505C
missense,VORINOSTAT,head and neck squamous cell carcinoma,sensitive,FBXW7,R505C,FBXW7 R505C
missense,AZD-4547,non-small cell lung carcinoma (disease),resistant,FGFR1,V561M,FGFR1 V561M
missense,DEBIO-1347,cancer,resistant,FGFR2,V564L,FGFR2 V564L
missense,LENVATINIB,cancer,sensitive,FGFR2,K660E,FGFR2 K660E
missense,PONATINIB,cancer,sensitive,FGFR2,K660E,FGFR2 K660E
missense,PAZOPANIB,cancer,sensitive,FGFR2,K660E,FGFR2 K660E
missense,Infigratinib,cancer,sensitive,FGFR2,K660E,FGFR2 K660E
missense,CEDIRANIB,cancer,sensitive,FGFR2,K660E,FGFR2 K660E
missense,AZD-4547,cancer,sensitive,FGFR2,K660E,FGFR2 K660E
missense,AZD-4547,cancer,resistant,FGFR2,V564F,FGFR2 V564F
missense,Infigratinib,cancer,resistant,FGFR2,V564F,FGFR2 V564F
missense,DEBIO-1347,cancer,sensitive,FGFR2,V564F,FGFR2 V564F
missense,Infigratinib,intrahepatic cholangiocarcinoma,sensitive,FGFR2,F276C,FGFR2 F276C
missense,PONATINIB,cancer,sensitive,FGFR2,N550H,FGFR2 N550H
missense,PONATINIB,cancer,sensitive,FGFR2,N550S,FGFR2 N550S
missense,PONATINIB,cancer,resistant,FGFR2,M538I,FGFR2 M538I
missense,PONATINIB,cancer,sensitive,FGFR2,N550K,FGFR2 N550K
missense,AZD-4547,endometrial cancer,resistant,FGFR2,N550K,FGFR2 N550K
missense,PONATINIB,cancer,sensitive,FGFR2,M536I,FGFR2 M536I
missense,NINTEDANIB,endometrial cancer,sensitive,FGFR2,S252W,FGFR2 S252W
missense,DEBIO-1347,endometrial cancer,sensitive,FGFR2,S252W,FGFR2 S252W
missense,PONATINIB,endometrial cancer,sensitive,FGFR2,S252W,FGFR2 S252W
missense,BRIVANIB,endometrial cancer,sensitive,FGFR2,S252W,FGFR2 S252W
missense,CEDIRANIB,endometrial cancer,sensitive,FGFR2,S252W,FGFR2 S252W
missense,AZD-4547,endometrial cancer,resistant,FGFR2,S252W,FGFR2 S252W
missense,RO4987655,endometrial carcinoma (disease),resistant,FGFR2,S252W,FGFR2 S252W
missense,SELUMETINIB,endometrial carcinoma (disease),resistant,FGFR2,S252W,FGFR2 S252W
missense,Derazantinib,endometrial cancer,sensitive,FGFR2,S252W,FGFR2 S252W
missense,RO-5126766 free base,endometrial carcinoma (disease),sensitive,FGFR2,S252W,FGFR2 S252W
missense,DEBIO-1347,cancer,resistant,FGFR2,V564I,FGFR2 V564I
missense,PONATINIB,cancer,sensitive,FGFR2,I548V,FGFR2 I548V
missense,PAZOPANIB,head and neck squamous cell carcinoma,sensitive,FGFR2,P253R,FGFR2 P253R
missense,PAZOPANIB,cancer,sensitive,FGFR2,K660N,FGFR2 K660N
missense,CEDIRANIB,cancer,sensitive,FGFR2,K660N,FGFR2 K660N
missense,Infigratinib,cancer,sensitive,FGFR2,K660N,FGFR2 K660N
missense,AZD-4547,cancer,sensitive,FGFR2,K660N,FGFR2 K660N
missense,LENVATINIB,cancer,sensitive,FGFR2,K660N,FGFR2 K660N
missense,PONATINIB,cancer,sensitive,FGFR2,K660N,FGFR2 K660N
missense,AZD-4547,cancer,sensitive,FGFR2,W290C,FGFR2 W290C
missense,PAZOPANIB,cancer,sensitive,FGFR2,W290C,FGFR2 W290C
missense,Infigratinib,cancer,sensitive,FGFR2,W290C,FGFR2 W290C
missense,CEDIRANIB,cancer,sensitive,FGFR2,W290C,FGFR2 W290C
missense,LENVATINIB,cancer,sensitive,FGFR2,W290C,FGFR2 W290C
missense,PONATINIB,cancer,sensitive,FGFR2,W290C,FGFR2 W290C
missense,DEBIO-1347,endometrial cancer,sensitive,FGFR2,N549K,FGFR2 N549K
missense,CEDIRANIB,endometrial cancer,sensitive,FGFR2,N549K,FGFR2 N549K
missense,Derazantinib,endometrial cancer,sensitive,FGFR2,N549K,FGFR2 N549K
missense,NINTEDANIB,endometrial cancer,resistant,FGFR2,N549K,FGFR2 N549K
missense,PONATINIB,endometrial cancer,sensitive,FGFR2,N549K,FGFR2 N549K
missense,PONATINIB,cancer,resistant,FGFR2,V565I,FGFR2 V565I
missense,PONATINIB,cancer,sensitive,FGFR2,L618M,FGFR2 L618M
missense,PONATINIB,cancer,sensitive,FGFR2,E566G,FGFR2 E566G
missense,Infigratinib,cancer,resistant,FGFR3,V555M,FGFR3 V555M
missense,AZD-4547,cancer,resistant,FGFR3,V555M,FGFR3 V555M
missense,LY-2874455,cancer,sensitive,FGFR3,V555M,FGFR3 V555M
missense,PONATINIB,cancer,sensitive,FGFR3,V555M,FGFR3 V555M
missense,DEBIO-1347,cancer,resistant,FGFR3,V555M,FGFR3 V555M
missense,Infigratinib,transitional cell carcinoma,resistant,FGFR3,V555M,FGFR3 V555M
missense,Infigratinib,cancer,resistant,FGFR3,V555L,FGFR3 V555L
missense,Infigratinib,transitional cell carcinoma,resistant,FGFR3,V555L,FGFR3 V555L
missense,LY-2874455,cancer,sensitive,FGFR3,L608V,FGFR3 L608V
missense,PONATINIB,cancer,sensitive,FGFR3,L608V,FGFR3 L608V
missense,AZD-4547,cancer,resistant,FGFR3,L608V,FGFR3 L608V
missense,Infigratinib,cancer,resistant,FGFR3,L608V,FGFR3 L608V
missense,DEBIO-1347,cancer,resistant,FGFR3,L608V,FGFR3 L608V
missense,CEDIRANIB,urinary bladder cancer,sensitive,FGFR3,S249C,FGFR3 S249C
missense,PONATINIB,cancer,sensitive,FGFR3,S249C,FGFR3 S249C
missense,DEBIO-1347,urinary bladder cancer,sensitive,FGFR3,S249C,FGFR3 S249C
missense,PAZOPANIB,renal pelvis urothelial carcinoma,sensitive,FGFR3,S249C,FGFR3 S249C
missense,Infigratinib,cancer,sensitive,FGFR3,S249C,FGFR3 S249C
missense,PONATINIB,urinary bladder cancer,sensitive,FGFR3,S249C,FGFR3 S249C
missense,AZD-4547,malignant urinary system neoplasm,sensitive,FGFR3,S249C,FGFR3 S249C
missense,NINTEDANIB,urinary bladder cancer,resistant,FGFR3,S249C,FGFR3 S249C
missense,Infigratinib,malignant urinary system neoplasm,sensitive,FGFR3,S249C,FGFR3 S249C
missense,Infigratinib,cancer,sensitive,FGFR3,R248C,FGFR3 R248C
missense,PAZOPANIB,cancer,sensitive,FGFR3,R248C,FGFR3 R248C
missense,DEBIO-1347,myeloid neoplasm,sensitive,FGFR3,F386L,FGFR3 F386L
missense,NINTEDANIB,urinary bladder cancer,resistant,FGFR3,Y375C,FGFR3 Y375C
missense,PONATINIB,urinary bladder cancer,sensitive,FGFR3,Y375C,FGFR3 Y375C
missense,CEDIRANIB,urinary bladder cancer,resistant,FGFR3,Y375C,FGFR3 Y375C
missense,DEBIO-1347,myeloid neoplasm,sensitive,FGFR3,Y373C,FGFR3 Y373C
missense,AZD-4547,cancer,resistant,FGFR3,K650E,FGFR3 K650E
missense,Infigratinib,cancer,resistant,FGFR3,K650E,FGFR3 K650E
missense,LY-2874455,cancer,sensitive,FGFR3,K650E,FGFR3 K650E
missense,ERDAFITINIB,cancer,sensitive,FGFR3,K650E,FGFR3 K650E
missense,DEBIO-1347,myeloid neoplasm,sensitive,FGFR3,K650E,FGFR3 K650E
missense,DEBIO-1347,cancer,sensitive,FGFR3,K650E,FGFR3 K650E
missense,PONATINIB,cancer,sensitive,FGFR3,K650E,FGFR3 K650E
missense,Infigratinib,head and neck squamous cell carcinoma,resistant,FGFR3,S131L,FGFR3 S131L
missense,DEBIO-1347,cancer,resistant,FGFR3,N540K,FGFR3 N540K
missense,ERDAFITINIB,cancer,sensitive,FGFR3,N540K,FGFR3 N540K
missense,Infigratinib,cancer,resistant,FGFR3,N540K,FGFR3 N540K
missense,LY-2874455,cancer,resistant,FGFR3,N540K,FGFR3 N540K
missense,AZD-4547,cancer,resistant,FGFR3,N540K,FGFR3 N540K
missense,PONATINIB,cancer,sensitive,FGFR3,N540K,FGFR3 N540K
missense,Derazantinib,urinary bladder cancer,sensitive,FGFR3,K652E,FGFR3 K652E
missense,CRENOLANIB,acute myeloid leukemia,sensitive,FLT3,D835X,FLT3 D835X
missense,SELINEXOR,acute myeloid leukemia,sensitive,FLT3,D835X,FLT3 D835X
missense,Sorafenib,acute myeloid leukemia,sensitive,FLT3,D835X,FLT3 D835X
missense,MIDOSTAURIN,cancer,sensitive,FLT3,R834Q,FLT3 R834Q
missense,MIDOSTAURIN,cancer,sensitive,FLT3,Y572C,FLT3 Y572C
missense,PEXIDARTINIB,cancer,resistant,FLT3,D835V,FLT3 D835V
missense,MIDOSTAURIN,acute myeloid leukemia,sensitive,FLT3,Y842C,FLT3 Y842C
missense,Imatinib,acute myeloid leukemia,resistant,FLT3,Y842C,FLT3 Y842C
missense,MIDOSTAURIN,cancer,sensitive,FLT3,D835Y,FLT3 D835Y
missense,PEXIDARTINIB,cancer,resistant,FLT3,D835Y,FLT3 D835Y
missense,TRETINOIN,acute promyelocytic leukemia,resistant,FLT3,D835Y,FLT3 D835Y
missense,CYTARABINE,acute promyelocytic leukemia,sensitive,FLT3,D835Y,FLT3 D835Y
missense,METHOTREXATE,acute promyelocytic leukemia,sensitive,FLT3,D835Y,FLT3 D835Y
missense,TRETINOIN,acute promyelocytic leukemia,sensitive,FLT3,D835Y,FLT3 D835Y
missense,MIDOSTAURIN,cancer,resistant,FLT3,S451F,FLT3 S451F
missense,CRENOLANIB,acute myeloid leukemia,sensitive,FLT3,D835H,FLT3 D835H
missense,MIDOSTAURIN,cancer,sensitive,FLT3,V592G,FLT3 V592G
missense,TRAMETINIB,uveal melanoma,sensitive,GNA11,Q209L,GNA11 Q209L
missense,SOTRASTAURIN ACETATE,uveal melanoma,sensitive,GNA11,Q209L,GNA11 Q209L
missense,BINIMETINIB,uveal melanoma,sensitive,GNA11,Q209L,GNA11 Q209L
missense,malathion,uveal melanoma,sensitive,GNA11,Q209L,GNA11 Q209L
missense,SOTRASTAURIN ACETATE,uveal melanoma,sensitive,GNAQ,Q209L,GNAQ Q209L
missense,TRAMETINIB,uveal melanoma,sensitive,GNAQ,Q209L,GNAQ Q209L
missense,TRAMETINIB,uveal melanoma,sensitive,GNAQ,Q209L,GNAQ Q209L
missense,malathion,uveal melanoma,sensitive,GNAQ,Q209L,GNAQ Q209L
missense,SELUMETINIB,uveal melanoma,sensitive,GNAQ,Q209L,GNAQ Q209L
missense,ENZASTAURIN,uveal melanoma,sensitive,GNAQ,Q209L,GNAQ Q209L
missense,SOTRASTAURIN ACETATE,uveal melanoma,sensitive,GNAQ,Q209L,GNAQ Q209L
missense,malathion,uveal melanoma,sensitive,GNAQ,Q209P,GNAQ Q209P
missense,SELUMETINIB,uveal melanoma,sensitive,GNAQ,Q209P,GNAQ Q209P
missense,SOTRASTAURIN ACETATE,uveal melanoma,sensitive,GNAQ,Q209P,GNAQ Q209P
missense,ENZASTAURIN,uveal melanoma,sensitive,GNAQ,Q209P,GNAQ Q209P
missense,TRAMETINIB,head and neck squamous cell carcinoma,sensitive,HRAS,Q61L,HRAS Q61L
missense,BINIMETINIB,squamous cell lung carcinoma,sensitive,HRAS,Q61L,HRAS Q61L
missense,BINIMETINIB,squamous cell lung carcinoma,sensitive,HRAS,Q61L,HRAS Q61L
missense,SELUMETINIB,squamous cell lung carcinoma,sensitive,HRAS,Q61L,HRAS Q61L
missense,BINIMETINIB,cancer,sensitive,HRAS,Q61L,HRAS Q61L
missense,BINIMETINIB,cancer,sensitive,HRAS,Q61L,HRAS Q61L
missense,SELUMETINIB,squamous cell lung carcinoma,sensitive,HRAS,Q61L,HRAS Q61L
missense,RIGOSERTIB,cancer,sensitive,HRAS,G12V,HRAS G12V
missense,BINIMETINIB,urinary bladder cancer,sensitive,HRAS,G12V,HRAS G12V
missense,SR9011,cancer,sensitive,HRAS,G12V,HRAS G12V
missense,BINIMETINIB,cancer,sensitive,HRAS,G12V,HRAS G12V
missense,CI-1040,melanoma (disease),sensitive,HRAS,G12V,HRAS G12V
missense,SELUMETINIB,urinary bladder cancer,sensitive,HRAS,G12V,HRAS G12V
missense,BINIMETINIB,cancer,sensitive,HRAS,G12V,HRAS G12V
missense,SR9009,cancer,sensitive,HRAS,G12V,HRAS G12V
missense,BINIMETINIB,cancer,sensitive,HRAS,Q61R,HRAS Q61R
missense,DASATINIB,intrahepatic cholangiocarcinoma,sensitive,IDH1,R132S,IDH1 R132S
missense,SARACATINIB,intrahepatic cholangiocarcinoma,sensitive,IDH1,R132S,IDH1 R132S
missense,DASATINIB,intrahepatic cholangiocarcinoma,sensitive,IDH1,R132C,IDH1 R132C
missense,OLAPARIB,sarcoma,sensitive,IDH1,R132C,IDH1 R132C
missense,OLAPARIB,sarcoma,resistant,IDH1,R132C,IDH1 R132C
missense,SARACATINIB,intrahepatic cholangiocarcinoma,sensitive,IDH1,R132C,IDH1 R132C
missense,Metformin,colorectal cancer,resistant,IDH1,R132H,IDH1 R132H
missense,NIRAPARIB,cancer,sensitive,IDH1,R132H,IDH1 R132H
missense,OLAPARIB,colon carcinoma,sensitive,IDH1,R132H,IDH1 R132H
missense,BERZOSERTIB,cancer,sensitive,IDH1,R132H,IDH1 R132H
missense,RUCAPARIB,cancer,sensitive,IDH1,R132H,IDH1 R132H
missense,DECITABINE,oligodendroglioma,sensitive,IDH1,R132H,IDH1 R132H
missense,AZACITIDINE,grade III astrocytoma,sensitive,IDH1,R132H,IDH1 R132H
missense,OLAPARIB,cancer,sensitive,IDH1,R132H,IDH1 R132H
missense,TEMOZOLOMIDE,glioma susceptibility 1,sensitive,IDH1,R132H,IDH1 R132H
missense,VANDETANIB,glioma susceptibility 1,sensitive,IDH1,R132H,IDH1 R132H
missense,Metformin,colorectal cancer,sensitive,IDH1,R132H,IDH1 R132H
missense,ENASIDENIB,acute myeloid leukemia,sensitive,IDH2,R140Q,IDH2 R140Q
missense,ENASIDENIB,glioma susceptibility 1,sensitive,IDH2,R140Q,IDH2 R140Q
missense,ENASIDENIB,glioma susceptibility 1,sensitive,IDH2,R172K,IDH2 R172K
missense,ENASIDENIB,colorectal cancer,sensitive,IDH2,R172K,IDH2 R172K
missense,ENASIDENIB,acute myeloid leukemia,sensitive,IDH2,R172K,IDH2 R172K
missense,RUXOLITINIB,B-cell childhood acute lymphoblastic leukemia,resistant,JAK2,R938Q,JAK2 R938Q
missense,Fedratinib,hematopoietic and lymphoid cell neoplasm,resistant,JAK2,R867Q,JAK2 R867Q
missense,MOMELOTINIB,hematopoietic and lymphoid cell neoplasm,resistant,JAK2,R867Q,JAK2 R867Q
missense,RUXOLITINIB,hematopoietic and lymphoid cell neoplasm,resistant,JAK2,R867Q,JAK2 R867Q
missense,RUXOLITINIB,cancer,sensitive,JAK2,V617F,JAK2 V617F
missense,Gandotinib,myeloproliferative neoplasm,sensitive,JAK2,V617F,JAK2 V617F
missense,PICTILISIB,cancer,sensitive,JAK2,V617F,JAK2 V617F
missense,RUXOLITINIB,cancer,sensitive,JAK2,V617F,JAK2 V617F
missense,RUXOLITINIB,bone marrow cancer,sensitive,JAK2,V617F,JAK2 V617F
missense,RUXOLITINIB,cancer,sensitive,JAK2,V617F,JAK2 V617F
missense,Imatinib,myeloid leukemia,resistant,JAK2,V617F,JAK2 V617F
missense,RUXOLITINIB,cancer,sensitive,JAK2,V617F,JAK2 V617F
missense,RUXOLITINIB,bone marrow cancer,sensitive,JAK2,V617F,JAK2 V617F
missense,NS-018,hematopoietic and lymphoid cell neoplasm,sensitive,JAK2,V617F,JAK2 V617F
missense,RUXOLITINIB,acute myeloid leukemia,sensitive,JAK2,V617F,JAK2 V617F
missense,RUXOLITINIB,cancer,resistant,JAK2,Y931C,JAK2 Y931C
missense,NS-018,acute myeloid leukemia,resistant,JAK3,A572V,JAK3 A572V
missense,TOFACITINIB,mature T-cell and NK-cell lymphoma,sensitive,JAK3,A572V,JAK3 A572V
missense,TOFACITINIB,cancer,sensitive,JAK3,A572V,JAK3 A572V
missense,TOFACITINIB,cancer,sensitive,JAK3,R172Q,JAK3 R172Q
missense,TOFACITINIB,hematopoietic and lymphoid cell neoplasm,sensitive,JAK3,G589D,JAK3 G589D
missense,TOFACITINIB,cancer,sensitive,JAK3,E183G,JAK3 E183G
missense,TOFACITINIB,hematopoietic and lymphoid cell neoplasm,sensitive,JAK3,H583Y,JAK3 H583Y
missense,TOFACITINIB,cancer,sensitive,JAK3,L156P,JAK3 L156P
missense,TOFACITINIB,hematopoietic and lymphoid cell neoplasm,sensitive,JAK3,M511I,JAK3 M511I
missense,RUXOLITINIB,cancer,resistant,JAK3,L857P,JAK3 L857P
missense,TOFACITINIB,cancer,sensitive,JAK3,L857P,JAK3 L857P
missense,TOFACITINIB,hematopoietic and lymphoid cell neoplasm,sensitive,JAK3,A573V,JAK3 A573V
missense,TOFACITINIB,cancer,sensitive,JAK3,V722I,JAK3 V722I
missense,RUXOLITINIB,cancer,sensitive,JAK3,V674A,JAK3 V674A
missense,TOFACITINIB,cancer,sensitive,JAK3,V674A,JAK3 V674A
missense,CABOZANTINIB,colorectal cancer,sensitive,KDR,R1032Q,KDR R1032Q
missense,LENVATINIB,colorectal cancer,sensitive,KDR,R1032Q,KDR R1032Q
missense,SUNITINIB,cancer,sensitive,KDR,A1065T,KDR A1065T
missense,SUNITINIB,cancer,sensitive,KDR,D717V,KDR D717V
missense,Sorafenib,colorectal cancer,resistant,KDR,L840F,KDR L840F
missense,REGORAFENIB,colorectal cancer,resistant,KDR,L840F,KDR L840F
missense,NILOTINIB,cancer,sensitive,KIT,V560G,KIT V560G
missense,PONATINIB,cancer,sensitive,KIT,V560G,KIT V560G
missense,Imatinib,gastrointestinal stromal tumor,resistant,KIT,D820N,KIT D820N
missense,Imatinib,gastrointestinal stromal tumor,sensitive,KIT,T670I,KIT T670I
missense,Imatinib,melanoma (disease),resistant,KIT,T670I,KIT T670I
missense,NILOTINIB,melanoma (disease),resistant,KIT,T670I,KIT T670I
missense,DASATINIB,melanoma (disease),resistant,KIT,T670I,KIT T670I
missense,PONATINIB,cancer,sensitive,KIT,T670I,KIT T670I
missense,SUNITINIB,melanoma (disease),sensitive,KIT,T670I,KIT T670I
missense,Imatinib,cancer,resistant,KIT,D816F,KIT D816F
missense,Imatinib,cancer,resistant,KIT,V654A,KIT V654A
missense,PONATINIB,cancer,sensitive,KIT,V654A,KIT V654A
missense,CYTARABINE,acute myeloid leukemia,sensitive,KIT,D816V,KIT D816V
missense,DASATINIB,acute myeloid leukemia,sensitive,KIT,D816V,KIT D816V
missense,Sorafenib,hematopoietic and lymphoid cell neoplasm,resistant,KIT,D816V,KIT D816V
missense,Flumatinib,cancer,resistant,KIT,D816V,KIT D816V
missense,PONATINIB,cancer,resistant,KIT,D816V,KIT D816V
missense,Imatinib,hematopoietic and lymphoid cell neoplasm,resistant,KIT,D816V,KIT D816V
missense,FF-10101-01,hematopoietic and lymphoid cell neoplasm,sensitive,KIT,D816V,KIT D816V
missense,Imatinib,Indication other than cancer,resistant,KIT,D816V,KIT D816V
missense,Imatinib,cancer,resistant,KIT,D816V,KIT D816V
missense,NILOTINIB,cancer,resistant,KIT,D816V,KIT D816V
missense,QUIZARTINIB,cancer,resistant,KIT,D816V,KIT D816V
missense,CABOZANTINIB,cancer,resistant,KIT,D816V,KIT D816V
missense,SUNITINIB,cancer,resistant,KIT,D816V,KIT D816V
missense,SUNITINIB,cancer,resistant,KIT,D816V,KIT D816V
missense,Sorafenib,melanoma (disease),sensitive,KIT,D820Y,KIT D820Y
missense,DASATINIB,melanoma (disease),sensitive,KIT,D820Y,KIT D820Y
missense,Imatinib,melanoma (disease),resistant,KIT,D820Y,KIT D820Y
missense,DASATINIB,melanoma (disease),sensitive,KIT,L576P,KIT L576P
missense,DASATINIB,melanoma (disease),sensitive,KIT,L576P,KIT L576P
missense,Sorafenib,melanoma (disease),sensitive,KIT,L576P,KIT L576P
missense,NILOTINIB,melanoma (disease),sensitive,KIT,L576P,KIT L576P
missense,Sorafenib,melanoma (disease),sensitive,KIT,N505I,KIT N505I
missense,Imatinib,melanoma (disease),sensitive,KIT,N505I,KIT N505I
missense,NILOTINIB,melanoma (disease),sensitive,KIT,V559A,KIT V559A
missense,Imatinib,melanoma (disease),sensitive,KIT,V559A,KIT V559A
missense,Imatinib,gastrointestinal stromal tumor,resistant,KIT,V559A,KIT V559A
missense,NILOTINIB,melanoma (disease),sensitive,KIT,V559D,KIT V559D
missense,Flumatinib,cancer,sensitive,KIT,V559D,KIT V559D
missense,Imatinib,cancer,sensitive,KIT,V559D,KIT V559D
missense,Imatinib,cancer,sensitive,KIT,V559D,KIT V559D
missense,SUNITINIB,cancer,sensitive,KIT,V559D,KIT V559D
missense,DASATINIB,cancer,sensitive,KIT,V559D,KIT V559D
missense,PONATINIB,cancer,sensitive,KIT,V559D,KIT V559D
missense,NILOTINIB,melanoma (disease),sensitive,KIT,W557R,KIT W557R
missense,Imatinib,melanoma (disease),resistant,KIT,A829P,KIT A829P
missense,PONATINIB,cancer,sensitive,KIT,A829P,KIT A829P
missense,SUNITINIB,melanoma (disease),resistant,KIT,A829P,KIT A829P
missense,DASATINIB,melanoma (disease),sensitive,KIT,A829P,KIT A829P
missense,NILOTINIB,melanoma (disease),sensitive,KIT,A829P,KIT A829P
missense,Sorafenib,thymic carcinoma,sensitive,KIT,D820E,KIT D820E
missense,PONATINIB,cancer,sensitive,KIT,D820E,KIT D820E
missense,Imatinib,thymic carcinoma,sensitive,KIT,Y553N,KIT Y553N
missense,Imatinib,cancer,sensitive,KIT,Y578C,KIT Y578C
missense,Ripretinib,mast cell neoplasm,sensitive,KIT,D816Y,KIT D816Y
missense,Imatinib,cancer,resistant,KIT,D816Y,KIT D816Y
missense,Imatinib,cancer,resistant,KIT,D816Y,KIT D816Y
missense,Flumatinib,cancer,resistant,KIT,D816Y,KIT D816Y
missense,SUNITINIB,cancer,resistant,KIT,D816Y,KIT D816Y
missense,Imatinib,chronic leukemia,sensitive,KIT,M541L,KIT M541L
missense,Imatinib,gastrointestinal stromal tumor,sensitive,KIT,K642E,KIT K642E
missense,NILOTINIB,melanoma (disease),sensitive,KIT,K642E,KIT K642E
missense,Imatinib,vulvar melanoma (disease),sensitive,KIT,K642E,KIT K642E
missense,PONATINIB,gastrointestinal stromal tumor,sensitive,KIT,K642E,KIT K642E
missense,REGORAFENIB,gastrointestinal stromal tumor,sensitive,KIT,K642E,KIT K642E
missense,DASATINIB,cancer,sensitive,KIT,N822I,KIT N822I
missense,Imatinib,cancer,resistant,KIT,N822I,KIT N822I
missense,PONATINIB,childhood leukemia,sensitive,KIT,N822K,KIT N822K
missense,Ripretinib,acute myeloid leukemia,sensitive,KIT,N822K,KIT N822K
missense,Flumatinib,cancer,sensitive,KIT,N822K,KIT N822K
missense,SUNITINIB,cancer,sensitive,KIT,N822K,KIT N822K
missense,Imatinib,gastrointestinal stromal tumor,resistant,KIT,N822K,KIT N822K
missense,Imatinib,cancer,resistant,KIT,N822K,KIT N822K
missense,Imatinib,mucosal melanoma,sensitive,KIT,C443S,KIT C443S
missense,MOTESANIB,cancer,sensitive,KIT,Y823D,KIT Y823D
missense,MOTESANIB,cancer,sensitive,KIT,V560D,KIT V560D
missense,Imatinib,cancer,sensitive,KIT,V560D,KIT V560D
missense,SUNITINIB,cancer,sensitive,KIT,V560D,KIT V560D
missense,REGORAFENIB,cancer,sensitive,KIT,V560D,KIT V560D
missense,Sorafenib,cancer,sensitive,KIT,V560D,KIT V560D
missense,DASATINIB,cancer,sensitive,KIT,V560D,KIT V560D
missense,NILOTINIB,melanoma (disease),sensitive,KIT,V560D,KIT V560D
missense,PONATINIB,cancer,sensitive,KIT,V560D,KIT V560D
missense,PONATINIB,cancer,sensitive,KIT,D816H,KIT D816H
missense,REGORAFENIB,cancer,resistant,KIT,D816H,KIT D816H
missense,Flumatinib,cancer,sensitive,KIT,D816H,KIT D816H
missense,SUNITINIB,cancer,sensitive,KIT,D816H,KIT D816H
missense,NILOTINIB,mast cell leukemia,sensitive,KIT,S476I,KIT S476I
missense,MIDOSTAURIN,mast cell leukemia,sensitive,KIT,S476I,KIT S476I
missense,Imatinib,cancer,resistant,KIT,H697Y,KIT H697Y
missense,SUNITINIB,cancer,sensitive,KIT,H697Y,KIT H697Y
missense,Imatinib,cancer,sensitive,KIT,W557G,KIT W557G
missense,TRAMETINIB,pancreatic adenocarcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,RIGOSERTIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,MK-1775,cancer,sensitive,KRAS,G12D,KRAS G12D
missense,AZD-8055,cancer,sensitive,KRAS,G12D,KRAS G12D
missense,Sonolisib,lung adenocarcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,SELUMETINIB,lung cancer,sensitive,KRAS,G12D,KRAS G12D
missense,NERATINIB,colorectal cancer,resistant,KRAS,G12D,KRAS G12D
missense,SUNITINIB,colorectal cancer,resistant,KRAS,G12D,KRAS G12D
missense,SELUMETINIB,lung adenocarcinoma,resistant,KRAS,G12D,KRAS G12D
missense,BUPARLISIB,gastric carcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,BINIMETINIB,ovarian epithelial tumor,sensitive,KRAS,G12D,KRAS G12D
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,resistant,KRAS,G12D,KRAS G12D
missense,ZSTK-474,colorectal cancer,sensitive,KRAS,G12D,KRAS G12D
missense,Gemcitabine,exocrine pancreatic carcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,SELUMETINIB,lung adenocarcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,PONATINIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,TRAMETINIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,COPANLISIB,biliary tract cancer,sensitive,KRAS,G12D,KRAS G12D
missense,REFAMETINIB,biliary tract cancer,sensitive,KRAS,G12D,KRAS G12D
missense,PICTILISIB,myelodysplastic/myeloproliferative Neoplasm,sensitive,KRAS,G12D,KRAS G12D
missense,NERATINIB,colorectal cancer,resistant,KRAS,G12D,KRAS G12D
missense,TRAMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,malathion,cholangiocarcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,TRAMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,LY-294002,cancer,sensitive,KRAS,G12D,KRAS G12D
missense,PD-0325901,lung adenocarcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,PICTILISIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,SELUMETINIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,PICTILISIB,exocrine pancreatic carcinoma,resistant,KRAS,G12D,KRAS G12D
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12D,KRAS G12D
missense,TRAMETINIB,head and neck squamous cell carcinoma,sensitive,KRAS,G12V,KRAS G12V
missense,SELUMETINIB,ovarian serous adenocarcinoma,sensitive,KRAS,G12V,KRAS G12V
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12V,KRAS G12V
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12V,KRAS G12V
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,resistant,KRAS,G12V,KRAS G12V
missense,BINIMETINIB,lung adenocarcinoma,resistant,KRAS,G12V,KRAS G12V
missense,PIMASERTIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12V,KRAS G12V
missense,ALPELISIB,colorectal cancer,sensitive,KRAS,G12V,KRAS G12V
missense,SUNITINIB,colorectal cancer,resistant,KRAS,G12V,KRAS G12V
missense,BINIMETINIB,ovarian epithelial tumor,sensitive,KRAS,G12V,KRAS G12V
missense,SELUMETINIB,lung adenocarcinoma,resistant,KRAS,G12V,KRAS G12V
missense,NERATINIB,colorectal cancer,resistant,KRAS,G12V,KRAS G12V
missense,TRAMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12V,KRAS G12V
missense,SELUMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12V,KRAS G12V
missense,REGORAFENIB,colorectal cancer,resistant,KRAS,G12V,KRAS G12V
missense,TRAMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12V,KRAS G12V
missense,TRAMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12V,KRAS G12V
missense,REGORAFENIB,colorectal cancer,sensitive,KRAS,G12V,KRAS G12V
missense,Pilaralisib,non-small cell lung carcinoma (disease),sensitive,KRAS,Q61K,KRAS Q61K
missense,BINIMETINIB,lung adenocarcinoma,resistant,KRAS,Q61K,KRAS Q61K
missense,SELUMETINIB,lung adenocarcinoma,resistant,KRAS,Q61K,KRAS Q61K
missense,BINIMETINIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12X,KRAS G12X
missense,COBIMETINIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12X,KRAS G12X
missense,COBIMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12X,KRAS G12X
missense,GEFITINIB,lung adenocarcinoma,resistant,KRAS,G12X,KRAS G12X
missense,Erlotinib,lung adenocarcinoma,resistant,KRAS,G12X,KRAS G12X
missense,PD-0325901,cancer,sensitive,KRAS,G12X,KRAS G12X
missense,SALIRASIB,cancer,sensitive,KRAS,G12X,KRAS G12X
missense,FLUOROURACIL,colon carcinoma,sensitive,KRAS,A59T,KRAS A59T
missense,Irinotecan,colon carcinoma,sensitive,KRAS,A59T,KRAS A59T
missense,Leucovorin,colon carcinoma,sensitive,KRAS,A59T,KRAS A59T
missense,SELUMETINIB,lung adenocarcinoma,resistant,KRAS,G13C,KRAS G13C
missense,BINIMETINIB,lung adenocarcinoma,resistant,KRAS,G13C,KRAS G13C
missense,TRAMETINIB,colorectal cancer,sensitive,KRAS,G12C,KRAS G12C
missense,SUNITINIB,colorectal cancer,resistant,KRAS,G12C,KRAS G12C
missense,BINIMETINIB,lung adenocarcinoma,resistant,KRAS,G12C,KRAS G12C
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,SELUMETINIB,lung adenocarcinoma,resistant,KRAS,G12C,KRAS G12C
missense,PD-0325901,pancreatic adenocarcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,COBIMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12C,KRAS G12C
missense,SELUMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12C,KRAS G12C
missense,SELUMETINIB,pancreatic adenocarcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12C,KRAS G12C
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,resistant,KRAS,G12C,KRAS G12C
missense,COBIMETINIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,GEDATOLISIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12C,KRAS G12C
missense,TRAMETINIB,lung cancer,sensitive,KRAS,G12C,KRAS G12C
missense,TRAMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,TRAMETINIB,pancreatic adenocarcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,REFAMETINIB,pancreatic adenocarcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12C,KRAS G12C
missense,Ulixertinib,exocrine pancreatic carcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,Sorafenib,non-small cell lung carcinoma (disease),sensitive,KRAS,G12C,KRAS G12C
missense,PICTILISIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12C,KRAS G12C
missense,AFATINIB,lung adenocarcinoma,sensitive,KRAS,G12C,KRAS G12C
missense,SELUMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12C,KRAS G12C
missense,COBIMETINIB,lymphatic system cancer,sensitive,KRAS,R149G,KRAS R149G
missense,SALIRASIB,cancer,sensitive,KRAS,G13X,KRAS G13X
missense,GEFITINIB,lung adenocarcinoma,resistant,KRAS,G13X,KRAS G13X
missense,PAZOPANIB,thyroid cancer,sensitive,KRAS,G12R,KRAS G12R
missense,SUNITINIB,colorectal cancer,resistant,KRAS,G12R,KRAS G12R
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,resistant,KRAS,G12R,KRAS G12R
missense,TRAMETINIB,thyroid cancer,sensitive,KRAS,G12R,KRAS G12R
missense,BINIMETINIB,lung adenocarcinoma,resistant,KRAS,G12R,KRAS G12R
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,G12R,KRAS G12R
missense,SELUMETINIB,lung adenocarcinoma,resistant,KRAS,G12R,KRAS G12R
missense,PAZOPANIB,thyroid cancer,sensitive,KRAS,G12R,KRAS G12R
missense,TRAMETINIB,thyroid cancer,sensitive,KRAS,G12R,KRAS G12R
missense,REGORAFENIB,colorectal cancer,resistant,KRAS,G13D,KRAS G13D
missense,PIMASERTIB,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,REGORAFENIB,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,RO4987655,colorectal adenocarcinoma,sensitive,KRAS,G13D,KRAS G13D
missense,PIMASERTIB,colorectal cancer,resistant,KRAS,G13D,KRAS G13D
missense,PALBOCICLIB,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,TRAMETINIB,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,RIGOSERTIB,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,RO-5126766 free base,colorectal adenocarcinoma,sensitive,KRAS,G13D,KRAS G13D
missense,NERATINIB,colorectal cancer,resistant,KRAS,G13D,KRAS G13D
missense,REGORAFENIB,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,SELUMETINIB,colorectal adenocarcinoma,sensitive,KRAS,G13D,KRAS G13D
missense,COBIMETINIB,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,SUNITINIB,colorectal cancer,resistant,KRAS,G13D,KRAS G13D
missense,PIMASERTIB,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,Sorafenib,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,TRAMETINIB,colon carcinoma,sensitive,KRAS,G13D,KRAS G13D
missense,PIMASERTIB,colorectal cancer,sensitive,KRAS,G13D,KRAS G13D
missense,REGORAFENIB,colorectal cancer,resistant,KRAS,G12A,KRAS G12A
missense,PANOBINOSTAT,plasma cell myeloma,sensitive,KRAS,G12A,KRAS G12A
missense,CUDC-907,plasma cell myeloma,sensitive,KRAS,G12A,KRAS G12A
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,resistant,KRAS,Q61R,KRAS Q61R
missense,SELUMETINIB,pancreatic ductal adenocarcinoma,sensitive,KRAS,Q61R,KRAS Q61R
missense,CUDC-907,non-small cell lung carcinoma (disease),sensitive,KRAS,Q61H,KRAS Q61H
missense,TRAMETINIB,colorectal cancer,resistant,KRAS,Q61H,KRAS Q61H
missense,SELUMETINIB,lung adenocarcinoma,resistant,KRAS,Q61H,KRAS Q61H
missense,PICTILISIB,non-small cell lung carcinoma (disease),resistant,KRAS,Q61H,KRAS Q61H
missense,BINIMETINIB,lung adenocarcinoma,resistant,KRAS,Q61H,KRAS Q61H
missense,Sorafenib,ovarian carcinoma,sensitive,KRAS,Q61H,KRAS Q61H
missense,AFATINIB,lung adenocarcinoma,sensitive,KRAS,G12S,KRAS G12S
missense,TRAMETINIB,lung cancer,resistant,KRAS,G12S,KRAS G12S
missense,PIMASERTIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12S,KRAS G12S
missense,REGORAFENIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12S,KRAS G12S
missense,PIMASERTIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12S,KRAS G12S
missense,Sorafenib,non-small cell lung carcinoma (disease),sensitive,KRAS,G12S,KRAS G12S
missense,BINIMETINIB,lung adenocarcinoma,resistant,KRAS,G12S,KRAS G12S
missense,PD-0325901,lung cancer,resistant,KRAS,G12S,KRAS G12S
missense,RIGOSERTIB,lung cancer,sensitive,KRAS,G12S,KRAS G12S
missense,SELUMETINIB,lung cancer,sensitive,KRAS,G12S,KRAS G12S
missense,SELUMETINIB,lung adenocarcinoma,resistant,KRAS,G12S,KRAS G12S
missense,TRAMETINIB,lung cancer,sensitive,KRAS,G12S,KRAS G12S
missense,REFAMETINIB,lung cancer,resistant,KRAS,G12S,KRAS G12S
missense,GEDATOLISIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12S,KRAS G12S
missense,BINIMETINIB,lung cancer,sensitive,KRAS,G12S,KRAS G12S
missense,BINIMETINIB,exocrine pancreatic carcinoma,sensitive,KRAS,G12S,KRAS G12S
missense,SUNITINIB,colorectal cancer,resistant,KRAS,G12S,KRAS G12S
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12S,KRAS G12S
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12S,KRAS G12S
missense,PIMASERTIB,non-small cell lung carcinoma (disease),sensitive,KRAS,G12S,KRAS G12S
missense,PD-0325901,colorectal cancer,sensitive,KRAS,A146T,KRAS A146T
missense,CI-1040,cancer,sensitive,MAP2K1,F53S,MAP2K1 F53S
missense,TRAMETINIB,colorectal cancer,sensitive,MAP2K1,K57T,MAP2K1 K57T
missense,TRAMETINIB,colorectal cancer,sensitive,MAP2K1,K57T,MAP2K1 K57T
missense,REGORAFENIB,cancer,resistant,MAP2K1,V211D,MAP2K1 V211D
missense,PLX-4720,cancer,sensitive,MAP2K1,V211D,MAP2K1 V211D
missense,SELUMETINIB,cancer,resistant,MAP2K1,V211D,MAP2K1 V211D
missense,AZD-8330,cancer,resistant,MAP2K1,V211D,MAP2K1 V211D
missense,CI-1040,cancer,resistant,MAP2K1,L115A,MAP2K1 L115A
missense,DABRAFENIB,melanoma (disease),resistant,MAP2K1,K57E,MAP2K1 K57E
missense,AZD-8330,cancer,resistant,MAP2K1,K57N,MAP2K1 K57N
missense,PLX-4720,cancer,sensitive,MAP2K1,K57N,MAP2K1 K57N
missense,TRAMETINIB,colorectal cancer,sensitive,MAP2K1,K57N,MAP2K1 K57N
missense,REGORAFENIB,cancer,resistant,MAP2K1,K57N,MAP2K1 K57N
missense,SELUMETINIB,lung adenocarcinoma,sensitive,MAP2K1,K57N,MAP2K1 K57N
missense,TRAMETINIB,colorectal cancer,sensitive,MAP2K1,K57N,MAP2K1 K57N
missense,SELUMETINIB,cancer,sensitive,MAP2K1,K57N,MAP2K1 K57N
missense,TRAMETINIB,lymphatic system cancer,sensitive,MAP2K1,K57N,MAP2K1 K57N
missense,PLX-4720,cancer,sensitive,MAP2K1,F53L,MAP2K1 F53L
missense,SELUMETINIB,cancer,sensitive,MAP2K1,F53L,MAP2K1 F53L
missense,TRAMETINIB,colorectal cancer,sensitive,MAP2K1,F53L,MAP2K1 F53L
missense,REGORAFENIB,cancer,resistant,MAP2K1,F53L,MAP2K1 F53L
missense,TRAMETINIB,colorectal cancer,sensitive,MAP2K1,F53L,MAP2K1 F53L
missense,AZD-8330,cancer,resistant,MAP2K1,F53L,MAP2K1 F53L
missense,TRAMETINIB,colorectal cancer,sensitive,MAP2K1,C121S,MAP2K1 C121S
missense,AZD-8330,cancer,resistant,MAP2K1,C121S,MAP2K1 C121S
missense,REGORAFENIB,cancer,resistant,MAP2K1,C121S,MAP2K1 C121S
missense,SELUMETINIB,cancer,sensitive,MAP2K1,C121S,MAP2K1 C121S
missense,PLX-4720,cancer,sensitive,MAP2K1,C121S,MAP2K1 C121S
missense,SELUMETINIB,cancer,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,COBIMETINIB,lymphatic system cancer,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,COBIMETINIB,lymphatic system cancer,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,AZD-8330,cancer,resistant,MAP2K1,Q56P,MAP2K1 Q56P
missense,SELUMETINIB,lung adenocarcinoma,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,REGORAFENIB,cancer,resistant,MAP2K1,Q56P,MAP2K1 Q56P
missense,PLX-4720,cancer,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,PD-0325901,lung adenocarcinoma,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,SELUMETINIB,gastric carcinoma,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,TRAMETINIB,lung adenocarcinoma,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,TRAMETINIB,gastric carcinoma,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,REFAMETINIB,lung adenocarcinoma,sensitive,MAP2K1,Q56P,MAP2K1 Q56P
missense,AZD-8330,cancer,resistant,MAP2K1,F129L,MAP2K1 F129L
missense,PLX-4720,cancer,sensitive,MAP2K1,F129L,MAP2K1 F129L
missense,REGORAFENIB,cancer,resistant,MAP2K1,F129L,MAP2K1 F129L
missense,SELUMETINIB,cancer,sensitive,MAP2K1,F129L,MAP2K1 F129L
missense,SELUMETINIB,melanoma (disease),resistant,MAP2K1,P124L,MAP2K1 P124L
missense,COBIMETINIB,lymphatic system cancer,sensitive,MAP2K1,P124L,MAP2K1 P124L
missense,CI-1040,cancer,resistant,MAP2K1,L115P,MAP2K1 L115P
missense,CI-1040,melanoma (disease),resistant,MAP2K1,L115P,MAP2K1 L115P
missense,SELUMETINIB,melanoma (disease),resistant,MAP2K1,L115P,MAP2K1 L115P
missense,COBIMETINIB,lymphatic system cancer,sensitive,MAP2K1,P124Q,MAP2K1 P124Q
missense,AZD-8330,cancer,resistant,MAP2K1,I111S,MAP2K1 I111S
missense,SELUMETINIB,cancer,sensitive,MAP2K1,I111S,MAP2K1 I111S
missense,REGORAFENIB,cancer,resistant,MAP2K1,I111S,MAP2K1 I111S
missense,PLX-4720,cancer,sensitive,MAP2K1,I111S,MAP2K1 I111S
missense,TRAMETINIB,melanoma (disease),resistant,MAP2K1,V60E,MAP2K1 V60E
missense,DABRAFENIB,melanoma (disease),resistant,MAP2K1,V60E,MAP2K1 V60E
missense,CI-1040,melanoma (disease),resistant,MAP2K1,I103N,MAP2K1 I103N
missense,SELUMETINIB,melanoma (disease),resistant,MAP2K1,I103N,MAP2K1 I103N
missense,CI-1040,cancer,resistant,MAP2K1,I103N,MAP2K1 I103N
missense,CRIZOTINIB,lung carcinoma,sensitive,MET,T1010I,MET T1010I
missense,CRIZOTINIB,papillary renal cell carcinoma,sensitive,MET,D1228H,MET D1228H
missense,CRIZOTINIB,papillary renal cell carcinoma,sensitive,MET,F1200I,MET F1200I
missense,GLESATINIB,gastric carcinoma,sensitive,MET,Y1230C,MET Y1230C
missense,MERESTINIB,cancer,sensitive,MET,Y1230C,MET Y1230C
missense,CRIZOTINIB,gastric carcinoma,resistant,MET,Y1230C,MET Y1230C
missense,CAPMATINIB,gastric carcinoma,resistant,MET,Y1230C,MET Y1230C
missense,GLESATINIB,cancer,sensitive,MET,Y1230C,MET Y1230C
missense,CRIZOTINIB,papillary renal cell carcinoma,sensitive,MET,M1149T,MET M1149T
missense,CAPMATINIB,cancer,resistant,MET,D1228N,MET D1228N
missense,CRIZOTINIB,cancer,resistant,MET,D1228N,MET D1228N
missense,CABOZANTINIB,cancer,sensitive,MET,D1228N,MET D1228N
missense,MERESTINIB,cancer,sensitive,MET,D1228N,MET D1228N
missense,SAVOLITINIB,cancer,resistant,MET,D1228N,MET D1228N
missense,Sorafenib,ovarian carcinoma,sensitive,MET,N375S,MET N375S
missense,CRIZOTINIB,cancer,resistant,MET,Y1230H,MET Y1230H
missense,CAPMATINIB,cancer,resistant,MET,Y1230H,MET Y1230H
missense,CABOZANTINIB,cancer,sensitive,MET,Y1230H,MET Y1230H
missense,SAVOLITINIB,cancer,resistant,MET,Y1230H,MET Y1230H
missense,CRIZOTINIB,cancer,sensitive,MET,R988C,MET R988C
missense,CABOZANTINIB,cancer,sensitive,MET,D1228V,MET D1228V
missense,CRIZOTINIB,cancer,resistant,MET,D1228V,MET D1228V
missense,SAVOLITINIB,cancer,resistant,MET,D1228V,MET D1228V
missense,CAPMATINIB,cancer,resistant,MET,D1228V,MET D1228V
missense,GLESATINIB,cancer,sensitive,MET,D1228V,MET D1228V
missense,MERESTINIB,cancer,sensitive,MET,D1228V,MET D1228V
missense,NS-018,hematopoietic and lymphoid cell neoplasm,sensitive,MPL,W515L,MPL W515L
missense,RUXOLITINIB,cancer,sensitive,MPL,W515L,MPL W515L
missense,RUXOLITINIB,cancer,sensitive,MPL,W515L,MPL W515L
missense,PICTILISIB,cancer,sensitive,MPL,W515L,MPL W515L
missense,RUXOLITINIB,cancer,sensitive,MPL,W515L,MPL W515L
missense,RUXOLITINIB,cancer,sensitive,MPL,W515L,MPL W515L
missense,TEMOZOLOMIDE,glioma susceptibility 1,resistant,MSH6,T1219I,MSH6 T1219I
missense,VORINOSTAT,diffuse large B-cell lymphoma,sensitive,MYD88,L265P,MYD88 L265P
missense,IBRUTINIB,diffuse large B-cell lymphoma,resistant,MYD88,L265P,MYD88 L265P
missense,6-o-phosphoryl inosine monophosphate,B-cell lymphoma,sensitive,MYD88,L265P,MYD88 L265P
missense,IBRUTINIB,primary central nervous system lymphoma,sensitive,MYD88,L265P,MYD88 L265P
missense,BINIMETINIB,melanoma (disease),sensitive,NRAS,Q61L,NRAS Q61L
missense,VEMURAFENIB,melanoma (disease),resistant,NRAS,Q61L,NRAS Q61L
missense,SELUMETINIB,melanoma (disease),resistant,NRAS,Q61L,NRAS Q61L
missense,PLX-4720,melanoma (disease),resistant,NRAS,Q61L,NRAS Q61L
missense,TRAMETINIB,colorectal cancer,sensitive,NRAS,G12V,NRAS G12V
missense,ALPELISIB,rhabdomyosarcoma (disease),sensitive,NRAS,Q61H,NRAS Q61H
missense,BINIMETINIB,rhabdomyosarcoma (disease),sensitive,NRAS,Q61H,NRAS Q61H
missense,PIMASERTIB,non-small cell lung carcinoma (disease),sensitive,NRAS,Q61K,NRAS Q61K
missense,VEMURAFENIB,melanoma (disease),resistant,NRAS,Q61K,NRAS Q61K
missense,GEDATOLISIB,non-small cell lung carcinoma (disease),resistant,NRAS,Q61K,NRAS Q61K
missense,PIMASERTIB,non-small cell lung carcinoma (disease),sensitive,NRAS,Q61K,NRAS Q61K
missense,Sorafenib,non-small cell lung carcinoma (disease),sensitive,NRAS,Q61K,NRAS Q61K
missense,PIMASERTIB,non-small cell lung carcinoma (disease),sensitive,NRAS,Q61K,NRAS Q61K
missense,SELUMETINIB,melanoma (disease),sensitive,NRAS,Q61K,NRAS Q61K
missense,PIMASERTIB,non-small cell lung carcinoma (disease),sensitive,NRAS,Q61K,NRAS Q61K
missense,REGORAFENIB,non-small cell lung carcinoma (disease),sensitive,NRAS,Q61K,NRAS Q61K
missense,BINIMETINIB,melanoma (disease),sensitive,NRAS,Q61K,NRAS Q61K
missense,BINIMETINIB,acute myeloid leukemia,sensitive,NRAS,G12D,NRAS G12D
missense,ALPELISIB,acute myeloid leukemia,sensitive,NRAS,G12D,NRAS G12D
missense,BINIMETINIB,acute myeloid leukemia,sensitive,NRAS,G12D,NRAS G12D
missense,Dopamine,cancer,sensitive,NRAS,G12D,NRAS G12D
missense,BINIMETINIB,melanoma (disease),sensitive,NRAS,Q61R,NRAS Q61R
missense,SELUMETINIB,melanoma (disease),sensitive,NRAS,G13D,NRAS G13D
missense,VEMURAFENIB,melanoma (disease),resistant,NRAS,G13D,NRAS G13D
missense,Imatinib,childhood leukemia,sensitive,PDGFRA,H650Q,PDGFRA H650Q
missense,Imatinib,cancer,sensitive,PDGFRA,R841K,PDGFRA R841K
missense,CRENOLANIB,cancer,sensitive,PDGFRA,R841K,PDGFRA R841K
missense,Imatinib,cancer,sensitive,PDGFRA,G853D,PDGFRA G853D
missense,CRENOLANIB,cancer,sensitive,PDGFRA,G853D,PDGFRA G853D
missense,Imatinib,cancer,sensitive,PDGFRA,H845Y,PDGFRA H845Y
missense,CRENOLANIB,cancer,sensitive,PDGFRA,H845Y,PDGFRA H845Y
missense,Imatinib,cancer,sensitive,PDGFRA,Y849S,PDGFRA Y849S
missense,Imatinib,myeloid leukemia,sensitive,PDGFRA,Y849S,PDGFRA Y849S
missense,Imatinib,gastrointestinal stromal tumor,sensitive,PDGFRA,L221F,PDGFRA L221F
missense,CRENOLANIB,cancer,sensitive,PDGFRA,D842Y,PDGFRA D842Y
missense,Imatinib,cancer,sensitive,PDGFRA,D842Y,PDGFRA D842Y
missense,Imatinib,cancer,sensitive,PDGFRA,D846Y,PDGFRA D846Y
missense,Imatinib,cancer,sensitive,PDGFRA,P577S,PDGFRA P577S
missense,CRENOLANIB,cancer,sensitive,PDGFRA,P577S,PDGFRA P577S
missense,Imatinib,cancer,sensitive,PDGFRA,V561D,PDGFRA V561D
missense,Imatinib,cancer,resistant,PDGFRA,D842V,PDGFRA D842V
missense,DASATINIB,gastrointestinal stromal tumor,sensitive,PDGFRA,D842V,PDGFRA D842V
missense,NILOTINIB,cancer,resistant,PDGFRA,D842V,PDGFRA D842V
missense,SUNITINIB,cancer,resistant,PDGFRA,D842V,PDGFRA D842V
missense,CRENOLANIB,gastrointestinal stromal tumor,sensitive,PDGFRA,D842V,PDGFRA D842V
missense,REGORAFENIB,gastrointestinal stromal tumor,sensitive,PDGFRA,D842V,PDGFRA D842V
missense,CRENOLANIB,cancer,sensitive,PDGFRA,D842V,PDGFRA D842V
missense,Imatinib,cancer,sensitive,PDGFRA,N659K,PDGFRA N659K
missense,CRENOLANIB,cancer,sensitive,PDGFRA,N659K,PDGFRA N659K
missense,CRENOLANIB,cancer,sensitive,PDGFRA,V658A,PDGFRA V658A
missense,Imatinib,cancer,sensitive,PDGFRA,V658A,PDGFRA V658A
missense,Imatinib,myeloid leukemia,resistant,PDGFRA,N659S,PDGFRA N659S
missense,Imatinib,myeloid leukemia,sensitive,PDGFRA,R748G,PDGFRA R748G
missense,ALPELISIB,prostate cancer,sensitive,PTEN,A126G,PTEN A126G
missense,ALPELISIB,breast cancer,resistant,PTEN,C136Y,PTEN C136Y
missense,PICTILISIB,urinary bladder cancer,resistant,PTEN,N48I,PTEN N48I
missense,Cryptotanshinone,juvenile myelomonocytic leukemia,sensitive,PTPN11,E76K,PTPN11 E76K
missense,LETROZOLE,Her2-receptor negative breast cancer,resistant,RB1,H483Y,RB1 H483Y
missense,Ribociclib,Her2-receptor negative breast cancer,resistant,RB1,H483Y,RB1 H483Y
missense,Sorafenib,thyroid medullary carcinoma,sensitive,RET,C618R,RET C618R
missense,Sorafenib,cancer,sensitive,RET,V804M,RET V804M
missense,LAROTRECTINIB,thyroid medullary carcinoma,sensitive,RET,V804M,RET V804M
missense,Selpercatinib,thyroid medullary carcinoma,sensitive,RET,V804M,RET V804M
missense,PONATINIB,cancer,sensitive,RET,V804M,RET V804M
missense,VANDETANIB,cancer,resistant,RET,V804M,RET V804M
missense,VANDETANIB,cancer,sensitive,RET,L790F,RET L790F
missense,PONATINIB,cancer,sensitive,RET,L790F,RET L790F
missense,PONATINIB,cancer,sensitive,RET,A883F,RET A883F
missense,VANDETANIB,cancer,sensitive,RET,A883F,RET A883F
missense,Sorafenib,thyroid medullary carcinoma,sensitive,RET,C634F,RET C634F
missense,Sorafenib,thyroid medullary carcinoma,sensitive,RET,C634W,RET C634W
missense,Sorafenib,thyroid carcinoma,sensitive,RET,C634W,RET C634W
missense,Agerafenib,thyroid medullary carcinoma,sensitive,RET,C634W,RET C634W
missense,PONATINIB,thyroid carcinoma,sensitive,RET,C634W,RET C634W
missense,AZD-1480,thyroid cancer,sensitive,RET,C634W,RET C634W
missense,CABOZANTINIB,thyroid carcinoma,sensitive,RET,C634W,RET C634W
missense,LAROTRECTINIB,thyroid medullary carcinoma,sensitive,RET,C634W,RET C634W
missense,Selpercatinib,thyroid medullary carcinoma,sensitive,RET,C634W,RET C634W
missense,LENVATINIB,thyroid cancer,sensitive,RET,C634W,RET C634W
missense,REGORAFENIB,thyroid cancer,sensitive,RET,C634W,RET C634W
missense,Sorafenib,thyroid medullary carcinoma,sensitive,RET,C634R,RET C634R
missense,VANDETANIB,cancer,sensitive,RET,C634R,RET C634R
missense,PONATINIB,cancer,sensitive,RET,C634R,RET C634R
missense,Sorafenib,cancer,sensitive,RET,C634R,RET C634R
missense,Sorafenib,cancer,sensitive,RET,C634R,RET C634R
missense,PONATINIB,cancer,sensitive,RET,C634Y,RET C634Y
missense,Sorafenib,thyroid medullary carcinoma,sensitive,RET,C634Y,RET C634Y
missense,VANDETANIB,cancer,resistant,RET,V804L,RET V804L
missense,PONATINIB,cancer,sensitive,RET,V804L,RET V804L
missense,PONATINIB,cancer,sensitive,RET,Y791F,RET Y791F
missense,VANDETANIB,cancer,sensitive,RET,Y791F,RET Y791F
missense,PONATINIB,cancer,sensitive,RET,E768D,RET E768D
missense,VANDETANIB,cancer,sensitive,RET,E768D,RET E768D
missense,Sorafenib,cancer,sensitive,RET,S891A,RET S891A
missense,VANDETANIB,cancer,sensitive,RET,S891A,RET S891A
missense,PONATINIB,cancer,sensitive,RET,S891A,RET S891A
missense,PONATINIB,cancer,sensitive,RET,D898V,RET D898V
missense,LAROTRECTINIB,thyroid medullary carcinoma,sensitive,RET,M918T,RET M918T
missense,Selpercatinib,thyroid medullary carcinoma,sensitive,RET,M918T,RET M918T
missense,VANDETANIB,small cell lung carcinoma,sensitive,RET,M918T,RET M918T
missense,Sorafenib,cancer,sensitive,RET,M918T,RET M918T
missense,PONATINIB,cancer,sensitive,RET,M918T,RET M918T
missense,CABOZANTINIB,thyroid medullary carcinoma,sensitive,RET,M918T,RET M918T
missense,CABOZANTINIB,thyroid medullary carcinoma,sensitive,RET,M918T,RET M918T
missense,PONATINIB,thyroid carcinoma,sensitive,RET,M918T,RET M918T
missense,PONATINIB,small cell lung carcinoma,sensitive,RET,M918T,RET M918T
missense,LAROTRECTINIB,cancer,sensitive,RET,M918T,RET M918T
missense,Selpercatinib,cancer,sensitive,RET,M918T,RET M918T
missense,VANDETANIB,cancer,sensitive,RET,M918T,RET M918T
missense,AZD-1480,thyroid medullary carcinoma,sensitive,RET,M918T,RET M918T
missense,Sorafenib,thyroid medullary carcinoma,sensitive,RET,M918T,RET M918T
missense,Sorafenib,colorectal cancer,sensitive,RET,M918T,RET M918T
missense,PONATINIB,cancer,sensitive,RET,E884K,RET E884K
missense,PONATINIB,cancer,sensitive,RET,Y806C,RET Y806C
missense,SONIDEGIB,cancer,resistant,SMO,N219D,SMO N219D
missense,VISMODEGIB,sarcoma,resistant,SMO,N219D,SMO N219D
missense,TALADEGIB,cancer,resistant,SMO,C469Y,SMO C469Y
missense,VISMODEGIB,cancer,resistant,SMO,C469Y,SMO C469Y
missense,SONIDEGIB,cancer,resistant,SMO,C469Y,SMO C469Y
missense,VISMODEGIB,cancer,resistant,SMO,F460L,SMO F460L
missense,VISMODEGIB,cancer,resistant,SMO,T241M,SMO T241M
missense,SONIDEGIB,cancer,resistant,SMO,T241M,SMO T241M
missense,TALADEGIB,cancer,resistant,SMO,T241M,SMO T241M
missense,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,D473G,SMO D473G
missense,VISMODEGIB,cancer,resistant,SMO,D473G,SMO D473G
missense,VISMODEGIB,cancer,resistant,SMO,D473G,SMO D473G
missense,SONIDEGIB,skin basal cell carcinoma,resistant,SMO,D473G,SMO D473G
missense,TALADEGIB,cancer,sensitive,SMO,D473H,SMO D473H
missense,SONIDEGIB,skin basal cell carcinoma,resistant,SMO,D473H,SMO D473H
missense,malathion,cancer,sensitive,SMO,D473H,SMO D473H
missense,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,D473Y,SMO D473Y
missense,SONIDEGIB,cancer,resistant,SMO,E518K,SMO E518K
missense,VISMODEGIB,cancer,resistant,SMO,E518K,SMO E518K
missense,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,W281C,SMO W281C
missense,SONIDEGIB,cancer,resistant,SMO,W281C,SMO W281C
missense,TALADEGIB,cancer,resistant,SMO,W281C,SMO W281C
missense,VISMODEGIB,cancer,resistant,SMO,L412F,SMO L412F
missense,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,H231R,SMO H231R
missense,SONIDEGIB,cancer,resistant,SMO,V321M,SMO V321M
missense,VISMODEGIB,cancer,resistant,SMO,V321M,SMO V321M
missense,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,V321M,SMO V321M
missense,TALADEGIB,cancer,resistant,SMO,V321M,SMO V321M
missense,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,W281L,SMO W281L
missense,SONIDEGIB,cancer,resistant,SMO,S387N,SMO S387N
missense,VISMODEGIB,cancer,resistant,SMO,S387N,SMO S387N
missense,VISMODEGIB,sarcoma,resistant,SMO,S387N,SMO S387N
missense,SONIDEGIB,skin basal cell carcinoma,resistant,SMO,S533N,SMO S533N
missense,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,G497W,SMO G497W
missense,SONIDEGIB,cancer,resistant,SMO,I408V,SMO I408V
missense,VISMODEGIB,cancer,resistant,SMO,I408V,SMO I408V
missense,TALADEGIB,cancer,resistant,SMO,I408V,SMO I408V
missense,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,Q477E,SMO Q477E
missense,SONIDEGIB,cancer,resistant,SMO,D384N,SMO D384N
missense,VISMODEGIB,sarcoma,resistant,SMO,D384N,SMO D384N
missense,VISMODEGIB,cancer,resistant,SMO,D384N,SMO D384N
missense,VISMODEGIB,cancer,resistant,SMO,A459V,SMO A459V
missense,TALADEGIB,cancer,resistant,SMO,A459V,SMO A459V
missense,SONIDEGIB,cancer,resistant,SMO,A459V,SMO A459V
missense,VISMODEGIB,cancer,resistant,SMO,W535L,SMO W535L
missense,VISMODEGIB,cancer,resistant,SMO,W535L,SMO W535L
missense,SONIDEGIB,skin basal cell carcinoma,sensitive,SMO,W535L,SMO W535L
missense,Camptothecin,glioma susceptibility 1,sensitive,STAG2,S653*,STAG2 S653*
missense,OLAPARIB,glioma susceptibility 1,sensitive,STAG2,S653*,STAG2 S653*
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,STK11,Q37*,STK11 Q37*
missense,EXEMESTANE,triple-negative breast carcinoma,sensitive,STK11,F354L,STK11 F354L
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,STK11,W332*,STK11 W332*
missense,TRAMETINIB,non-small cell lung carcinoma (disease),sensitive,STK11,E199*,STK11 E199*
missense,APR-246,peritoneum cancer,sensitive,TP53,C135Y,TP53 C135Y
missense,APR-246,ovarian cancer,sensitive,TP53,P278R,TP53 P278R
missense,SELICICLIB,non-small cell lung carcinoma (disease),resistant,TP53,R175H,TP53 R175H
missense,GANETESPIB,breast cancer,sensitive,TP53,R175H,TP53 R175H
missense,ALVESPIMYCIN,cancer,sensitive,TP53,R175H,TP53 R175H
missense,VORINOSTAT,cancer,sensitive,TP53,R175H,TP53 R175H
missense,SELICICLIB,non-small cell lung carcinoma (disease),resistant,TP53,S215G,TP53 S215G
missense,APR-246,non-small cell lung carcinoma (disease),sensitive,TP53,R273H,TP53 R273H
missense,VEMURAFENIB,melanoma (disease),sensitive,TP53,D259Y,TP53 D259Y
missense,SELUMETINIB,melanoma (disease),sensitive,TP53,D259Y,TP53 D259Y
missense,APR-246,ovarian cancer,sensitive,TP53,R280K,TP53 R280K
missense,GANETESPIB,breast cancer,sensitive,TP53,R280K,TP53 R280K
missense,APR-246,non-small cell lung carcinoma (disease),sensitive,TP53,R248W,TP53 R248W
missense,Doxorubicin,breast cancer,sensitive,TP53,P72R,TP53 P72R
missense,DAUNORUBICIN,breast cancer,sensitive,TP53,P72R,TP53 P72R
missense,Epirubicin,breast cancer,sensitive,TP53,P72R,TP53 P72R
missense,Doxorubicin,sarcoma,sensitive,TP53,P72R,TP53 P72R
missense,IFOSFAMIDE,sarcoma,sensitive,TP53,P72R,TP53 P72R
missense,Irinotecan,non-small cell lung carcinoma (disease),sensitive,TP53,P72R,TP53 P72R
missense,Cyclophosphamide,estrogen-receptor negative breast cancer,sensitive,TP53,P72R,TP53 P72R
missense,Doxorubicin,estrogen-receptor negative breast cancer,sensitive,TP53,P72R,TP53 P72R
missense,FLUOROURACIL,estrogen-receptor negative breast cancer,sensitive,TP53,P72R,TP53 P72R
missense,DAUNORUBICIN,breast cancer,sensitive,TP53,P72R,TP53 P72R
missense,GEDATOLISIB,non-small cell lung carcinoma (disease),sensitive,TP53,R158G,TP53 R158G
missense,APR-246,fallopian tube cancer,sensitive,TP53,C238F,TP53 C238F
missense,APR-246,ovarian cancer,sensitive,TP53,L111Q,TP53 L111Q
missense,GANETESPIB,cancer,sensitive,TP53,R248Q,TP53 R248Q
missense,NAPABUCASIN,colorectal cancer,sensitive,TP53,R248Q,TP53 R248Q
missense,APR-246,ovarian cancer,sensitive,TP53,R248Q,TP53 R248Q
missense,TANESPIMYCIN,colorectal cancer,sensitive,TP53,R248Q,TP53 R248Q
missense,SELICICLIB,non-small cell lung carcinoma (disease),resistant,TP53,P98A,TP53 P98A
missense,APR-246,small cell lung carcinoma,sensitive,TP53,Y163C,TP53 Y163C
missense,APR-246,small cell lung carcinoma,sensitive,TP53,R273L,TP53 R273L
missense,SELICICLIB,non-small cell lung carcinoma (disease),resistant,TP53,Y234C,TP53 Y234C
missense,TANESPIMYCIN,breast cancer,sensitive,TP53,L194F,TP53 L194F
missense,GANETESPIB,breast cancer,sensitive,TP53,L194F,TP53 L194F
missense,TANESPIMYCIN,breast cancer,sensitive,TP53,L194F,TP53 L194F
missense,VORINOSTAT,breast cancer,sensitive,TP53,L194F,TP53 L194F
missense,VORINOSTAT,breast cancer,sensitive,TP53,L194F,TP53 L194F
missense,GANETESPIB,ovarian cancer,sensitive,TP53,S241F,TP53 S241F
missense,APR-246,small cell lung carcinoma,sensitive,TP53,S241F,TP53 S241F
missense,SELICICLIB,non-small cell lung carcinoma (disease),resistant,TP53,A159V,TP53 A159V
missense,SELICICLIB,non-small cell lung carcinoma (disease),resistant,TP53,Y220C,TP53 Y220C
missense,APR-246,ovarian cancer,sensitive,TP53,Y163H,TP53 Y163H
missense,APR-246,acute myeloid leukemia,sensitive,TP53,V173M,TP53 V173M
missense,IBRUTINIB,mantle cell lymphoma,sensitive,TP53,G244S,TP53 G244S
missense,APR-246,ovarian cancer,sensitive,TP53,P151H,TP53 P151H
